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1 Introduction 
1.1 The PI3K/AKT pathway  
 
 Kinases of the PI3K family are activated in a receptor tyrosine kinase (RTK) dependent 
manner. When bound to ligands such as insulin or insulin-like growth factor 1 (IGF1), RTKs undergo 
autophosphorylation and PI3K is recruited to the membrane and activated, either by directly binding 
phosphorylated tyrosine residues on the activated receptor with two SH2 domains in the regulatory 
subunit or indirectly, by interaction with receptor associated adaptor molecules like insulin-
receptor-substrate (IRS). Alternatively, PI3K can be activated by G-protein coupled receptors 
(GPCRs), by interaction with G-proteins such as Ras or tyrosine kinases like Src which phosphorylate 
their regulatory subunit [1-2]. Upon activation, PI3K phosphorylates membrane bound 
phosphatidylinositol-4,5-bisphosphate (PI[4,5]P2 or PIP2) to phosphatidylinositol-3,4,5-triphosphate 
(PI[3,4,5]P3 or PIP3) which then functions as a second messenger (Figure 1). Downstream molecules 
such as AKT and PDK1 are recruited to the plasma membrane (PM) by binding the second 
messenger PIP3 via their pleckstrin homology (PH) domain [3]. PI3K activity is associated with 
inhibition of apoptosis, cell cycle progression, DNA repair, metabolism, cell growth and translation. 
These diverse signals are mediated mainly by a subgroup of the cAMP-dependent, cGMP-
dependent, protein kinase C (AGC) kinase family like AKT, which is activated in a PIP3 dependent 
manner [4]. The phosphatase and tensin homologue on chromosome ten (PTEN) dephosphorylates 
PIP3 to PIP2 and thereby counteracts PI3K downstream activating function, thus acting as a tumor 
suppressor, i.e. a gene or gene product responsible for constraining cell proliferation and whose 
inactivation can contribute to cancer development. PI3K complexes are typically heterodimers, 
consisting of the p85 regulatory and the p110 catalytic subunits [5]. The regulatory p85 subunit 
mediates binding of PI3K to phosphotyrosine motifs on activated transmembrane receptors (e.g. 
PDGFR, EGFR, HER2) or to receptor associated adaptor proteins (e.g. Ras, IRS1), activation and 
localization of the enzyme. The catalytic subunit p110 is essential for generating PIP3 by 
phosphorylating the 3’OH group on the inositol ring of inositol phospholipids (Figure 1) [6]. 
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Figure 1 – Generation of PIP3 by PI3K and dephosphorylation to PIP2 by PTEN [1] 
 
There are 3 classes of PI3Ks, according to their structure and substrate specificity. Class I is 
further sub-categorized in class IA, the most relevant for cancer, which is activated as described 
above and class IB which is activated by GPCRs exclusively [1]. Class II PI3Ks have a single sub-unit 
and bind phosphoinositides (PI) or phosphatidylinositol-phosphates (PIP), however their cellular 
function is still unclear. Class III PI3Ks also consist of a single sub-unit (vPS34) and have been shown 
to be involved in membrane trafficking, autophagy and cell growth through activation of mammalian 
target of rapamycin (mTOR) in a nutrient dependent manner [7]. The PI3KCA gene encodes the 
p110α subunit isoform, which is associated with the most commonly known functions of PI3K 
downstream signaling. One of the most prominent downstream targets of PI3K is AKT, a 65 kDa 
serine-threonine Kinase and a pivotal component of the PI3K/AKT pathway. In the human genome, 
three genes are known to encode AKT-Family proteins, namely AKT1, AKT2 and AKT3. Unlike other 
members of the AGC kinase family, all AKT isoforms have an N terminal PH domain that mediates 
binding to PIs and a C-terminal catalytic domain with kinase activity. 
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Figure 2 – The PI3K/AKT Pathway and downstream targets. 
PI3K is activated by ligand-bound RTKs directly or by a number of RTK-coupled kinases (e.g. Ras, Src, IRS) and 
phosphorylates PI[4,5]P2 to PI[3,4,5]P3. AKT binds PIP3 and is recruited to the plasma membrane which allows PDK1 to 
phosphorylate AKT on T308, which is essential for activation. Shown in yellow are some of the known targets of AKT. 
  
AKT is recruited to the plasma membrane following generation of the second messenger 
molecule PIP3 by PI3K and is then phosphorylated by PDK1 at Thr308 which is essential for AKT 
activation [8]. However, full activity of AKT also requires a second phosphorylation at the C-terminal 
Ser473, which is thought to be carried out by a second PIP-dependent kinase – referred to as “PDK2” 
[9] - and likely to be mTOR kinase in the mTORC2/MIP1/SIN1 context [10-11]. AKT is a central 
platform for signal transduction and plays a role in inhibition of mitochondria-mediated and Fas-L 
mediated apoptosis (e.g. by inhibiting BAD, GSK3), cell cycle regulation (e.g. by inhibiting FoxO-3a, 
p53), promoting transcription and translation (e.g. by inhibiting TSC1/2 and activating NFκB). AKT 
activates or inhibits a variety of substrates and downstream signals, the most important of which 
are listed in Table 1.  
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Protein Effect of phosphorylation Biological effect Reference 
BAD inhibition Anti apoptotic [12] 
Caspase 9 inhibition Anti apoptotic [6] 
FOXO1 inhibition Anti apoptotic [12] 
Mdm2 activation Anti apoptotic [5] 
IκB kinase (IKK) activation Anti apoptotic [12] 
CREB activation Anti apoptotic [12] 
FOXO4 inhibition of p27
Kip1
 Anti apoptotic [5] 
FOXO3A inhibition Anti apoptotic [5] 
hTERT activation Anti apoptotic [12] 
GSK3beta inhibition Proliferation [12] 
P21
Cip
 inhibition Proliferation [12] 
mTOR activation Proliferation [6] 
PDE3B inhibition Proliferation [6] 
p27
Kip1
 inhibition Proliferation [13] 
TSC2 Inhibition Cell growth [5] 
Table 1 – List of important published AKT substrates involved in cell survival, proliferation and growth. 
 
1.2 PDK1, a master regulator of the PI3K/AKT pathway 
 
 PDK1 was first identified in 1997 as the activator of AKT in the presence of PIP3 [9]. PDK1 is a 
556 amino acid, 68kDa serine/threonine kinase of the AGC protein kinase family, and responsible for 
phosphorylation and activation of several other AGC kinases, the most important of which are  
p70 ribosomal S6 kinase (S6K), p90 ribosomal S6 kinase (RSK), serum and glucocorticoid induced 
kinase (SGK), protein kinase C (PKC) isoforms and AKT. Regulation of PDK1 is not well understood, 
however it is likely that PDK1 is not directly activated by insulin stimulation [14] but is constitutively 
active in mammalian cells [4] owing to its ability to autophosphorylate its T-loop at Ser241 in trans in 
humans [15]. More recent data suggests that Ser241 phosphorylation alone is not enough for full 
activity, but that phosphorylation at three more tyrosines (Tyr9, Tyr373, Tyr376) - likely by v-Src - is 
needed for activity and recruitment to the plasma membrane [16]. Additionally, stabilization of 
PDK1 by the molecular chaperone HSP90 is essential for PDK1 activity because it protects it from 
proteasomal degradation. HSP90 inhibitors (e.g. geldanamycin, radicicol) disrupt the PDK1-HSP90 
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interaction leading to proteasomal degradation of PDK1 and to AKT dephosphorylation [17]. It has 
been reported that phosphorylated Tyr9 is the residue responsible for HSP90 dependent 
stabilization [18]. Evidence that PDK1 is an important activator of downstream AGC kinases comes 
from the fact that in PDK1 knock out cells, S6K, SGK, AKT [14], RSK and PKC [19] fail to be activated 
and AKT substrate levels are altered. Tumor suppressor p27Kip levels for instance are markedly 
increased and levels of cyclin D1 are decreased, which leads to G2-M arrest [20]. Furthermore PDK1 
knock out is embryonic lethal in mice and embryos show multiple developmental abnormalities in 
brain formation [21]. It also leads to pancreatic hypoplasia in mice when locally knocked out in 
pancreatic cells [22] and to cardiac arrest after 5-11 weeks of age by sensitizing cardiomyocytes to 
hypoxia [23]. Mice expressing hypomorphic PDK1, leading to a reduction of PDK1 levels by 90%, are 
viable but 40-50% smaller than PDK1 wild type mice which was linked to a decrease of cell volume in 
hypomorphic mice rather than cell number [21]. This establishes PDK1 as an important regulator of 
effector AGC kinases in the PI3K pathway, responsible for cell growth, proliferation and survival. 
 
1.2.1 Regulation of AKT by PDK1 
 
 AGC kinases are typically activated by phosphorylation at two sites. One is located in the 
activation loop (t-loop) the other is typically localized in a C terminal hydrophobic motif (H-motif) 
[4]. PDK1 exerts its growth and survival promoting function via AKT by phosphorylating the Thr308 
residue in the AKT t-loop. We will discuss the current model for this mechanism below. PDK1 
contains two domains, an N-terminal kinase domain (amino acids 70-359) and a PH domain (amino 
acids 459 - 550), the latter interacts with PIP3. It is currently not known what function the PDK1 PH 
domain plays in activating substrates, as PDK1 binding to PIP3 seems not to be required for its 
catalytic activity [24]. PIP3 binding has an enhancing effect on AKT activation by increasing co-
localization with AKT and thus bringing enzyme and substrate into close enough contact for PDK1 to 
phosphorylate AKT and activate it at a higher rate. This is supported by the fact that AKT 
phosphorylation levels are highest when incubated with phospholipid vesicles containing PIP3 at 
concentrations of 10µM in vitro [9]. Whether PDK1 and AKT localize to the plasma membrane only 
following PI3K stimulation is controversial. Some studies suggest that PDK1 and AKT translocate to 
the plasma membrane following PI3K stimulation [25-26], while other studies seem to suggest that a 
pool of PDK1 – which has a PH domain with higher affinity to PIP3 than AKT – must be bound 
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constitutively to the plasma membrane [24] and only recruitment of its substrate, AKT, allows 
activating phosphorylation to occur. Evidence for the latter scenario comes from experiments where 
AKT was forced to localize to the PM in unstimulated cells, by fusion with a membrane targeting 
motif, which led to full Thr308 phosphorylation of AKT [27]. While the PDK1/PIP3 interaction seems 
to play a minor role, binding of AKT to PIP3 via its PH domain is essential for its activation. PDK1 is 
unable to phosphorylate wild type AKT at Thr308 in the absence of PIP3 but can readily 
phosphorylate an AKT PH domain deletion mutant [28]. This data is supported by structural analysis 
that showed that the PH domain of AKT undergoes conformational change when bound to PIP3 
allwoing PDK1 to phosphorylate Thr308 [29]. The details of how this conformational change allows 
phosphorylation are not clear, but it could be that the AKT activation loop is exposed or that a 
docking site for PDK1 is revealed. Recently there has been an attempt to challenge this idea, with 
studies using PDK1 and AKT fused to complementary moieties to induce complex formation in the 
presence of various PI3K inhibitors. These showed that PDK1-AKT complex formation is sufficient for 
AKT activation independently of membrane localization and PIP3 [30]. This suggests once again that 
in endogenous conditions, PDK1/PIP3 interaction could play an enhancing role by increasing 
PDK1/AKT co-localization. A possible limitation of this study however, is that the artificial AKT-PDK1 
complexes may behave differently than its endogenous counterpart. The complementary moieties 
may influence the secondary structure such that an open conformation is mimicked and the PDK1 
phosphorylation site exposed. AKT stands out from the other AGC kinases because - like PDK1 - it 
has a PH domain which plays a role in its activation, a feature absent in other kinases of this family. 
However, just like other AGC kinases it does have a C-terminal hydrophobic motif which needs to be 
phosphorylated at Ser473 by mTORC2 to allow AKT to be fully activated.  
 
1.2.2 Other PDK1 substrates 
 
 Beyond activating AKT, PDK1 is also responsible for activation of SGK, PKC, RSK, and S6K 
which are agonists of cell growth and translation. SGK is involved in regulation of ion transport and 
S6K controls protein synthesis and amino acid storage. PKC-α is activated in a diacylglycerol 
dependent manner and activates gene transcription via the IKK/NFκB, Fos/Jun/AP1 and MAPK 
pathways [31]. RSK is involved cell growth and proliferation via the MAPK/ERK pathway [32]. Since 
these kinases lack a PH domain, the mechanism by which PDK1 activates them is PIP3 independent, 
 13 
 
somewhat different from AKT and takes place in the cytoplasm. These substrates have Ser/Thr 
residues in their t-loop and C-terminal hydrophobic motives, and phosphorylation of both residues is 
essential for their kinase activity as well [4]. The catalytic domain of PDK1 contains a hydrophobic 
pocket - called PKC related kinase 2 (PRK2) interacting fragment pocket ("PIF" pocket), and first 
identified as binding to PRK2 - that interacts with high affinity with phosphorylated hydrophobic 
motifs [33]. This first phosphorylation step on AGC kinases is carried out by as of yet unidentified H-
motif kinases in response to PI3K activation. When residues in the hydrophobic motif of SGK [34] 
and S6K [35] are mutated to acidic amino acids, mimicking phosphorylated residues, 
phosphorylation of their t-loop becomes uncoupled from PI3K activity, suggesting that H-motif 
kinases are PI3K dependent. Once the H-motif is phosphorylated, PDK1 is able to bind these AGC 
kinases and phosphorylate their t-loop: this second phosphorylation is the final step that leads to 
the formation of a small phosphate binding pocket in the AGC kinase domain, leading to a 
conformation change and intrinsic binding of the phosphorylated H-motif by the pocket, which 
stabilizes the AGC kinase in an active state [4]. PDK1 activates AKT in a PIP3 dependent manner at 
the plasma membrane and its other substrates in a PIP3 independent manner in the cytosol. 
Although the mechanisms PDK1 dependent AKT activation differs from the other PDK1 substrates, in 
both cases insulin and growth factor signaling does not directly stimulate PDK1 activity but rather 
affects its ability to bind substrates, via a preliminary phosphorylation step [36]. This unusual 
substrate-dependent activation mechanism shows that PDK1 is both an essential activator and 
dependent on either a second messenger or priming of its substrates by H-motif kinases, to create a 
docking site.  
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1.3 Oncogenic pathway alterations 
 
 Components of the PI3K pathway are often mutated, amplified or silenced in somatic and 
germ line cells, and are thought to be causal in cancer development [1, 37]. Table 2 gives an 
overview of reported alterations of the most important nodes of the PI3K pathway in a wide range 
of cancers.  
 
Oncogene Alteration Cancer Type Incidence % 
PTEN Loss of heterozygosity Gastric 25,3 
 Loss of heterozygosity Breast 24,9 
 Loss of heterozygosity Melanoma 37 
 Loss of heterozygosity Prostate 30 
 Loss of heterozygosity Glioblastoma 28 
 Mutation (Loss of function) Endometrial 38 
 Mutation (Loss of function) Brain 21 
 Mutation (Loss of function) Skin  17 
 Mutation (Loss of function) Prostate 14 
 Mutation (Loss of function) Colon  13 
 Mutation (Loss of function) Ovary 9 
 Mutation (Loss of function) Breast 6 
 Mutation (Loss of function) Hematopoietic and lymphoid tissue 6 
 Mutation (Loss of function) Stomach 6 
 Mutation (Loss of function) Liver 5 
 Mutation (Loss of function) Kidney 5 
 Mutation (Loss of function) Vulva 65 
 Mutation (Loss of function) Urinary tract 9 
 Mutation (Loss of function) Thyroid 5 
 Mutation (Loss of function) Lung 9 
PI3K p110α Mutation Breast 27 
 Mutation Endometrial 24 
 Mutation Colon 15 
 Mutation Upper digestive tract 11 
 Mutation Gastric 8 
 Mutation Pancreas 8 
 Mutation Ovarian 8 
 Mutation Liver 6 
 Mutation Brain 5,9 
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 Mutation Oesophageal 5 
 Mutation Lung  3 
 Mutation Melanoma 9 
 Mutation Urinary tract 17 
 Mutation Prostate 2 
 Mutation Thyroid 2 
PI3K p85a Mutation Glioblastoma 9 
 Mutation Ovarian 4 
 Mutation Colon 2 
AKT1 Mutation Breast 3,7 
 Mutation Colon 2,8 
 Mutation Ovarian 2 
 Mutation Lung 1,9 
 Amplification Gastric 20 
AKT2 Amplification Ovarian 14,1 
 Amplification Pancreas 20 
 Amplification Head and neck 30 
 Amplification Breast 3 
AKT3 Amplification Skin 1,5 
 Amplification Glioblastoma 2 
PDK1 Amplification and overexpression Breast 20 
Table 2 – Incidence of genetic alteration in the PI3K pathway. Adapted from Liu et al. [1]  
 
1.3.1 PTEN in cancer 
 
 PTEN is frequently mutated in human cancers [38]. The PI3K pathway was first linked to 
cancer in the 1990s, when PTEN was discovered to be a phosphatase with substrate specificity for 
PI3K products, and antagonizing PI3K function [1]. By reversing PI3K function it also inhibits 
activation of PIP3 dependent and cell cycle promoting kinases such as PDK1 and AKT, and thus acts 
as a tumor suppressor. Transcription of PTEN is under the control of pro-apoptotic transcription 
factor and master tumor suppressor p53, which therefore functions as a negative regulator of the 
entire PI3K signaling pathway synergistically with PTEN [39-40]. Microsatellite analyses showed that 
PTEN is mutated in 25-50% of glioblastomas [41], in 40-55% of sporadic prostate cancers [42] and in 
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35% of endometrial carcinomas [43-44]. These statistics illustrate how widespread PTEN alterations 
are in carcinogenesis.  
 
1.3.2 PI3K in cancer 
  
 Oncogenic PI3K mutations are exclusively somatic and result in constitutive activity of the 
kinase [45]. Missense mutations at two hotspot regions of the PIK3CA locus, exons 9 and 20, of the 
PI3KCA locus are the most commonly occurring PI3K mutations in cancer [46]. These mutations are 
located at the interfaces between p110 and p85 domains and may increase enzymatic activity by 
disrupting inter-domain interactions, resulting in changes in the kinase domain [1]. This in turn 
increases PIP3 levels, and leads to PDK1 dependent AKT activation that induces cellular 
transformation. Studies using comparative genomic hybridization have shown that the chromosome 
region 3q26 which contains PIK3CA, is amplified in approximately 40% of ovarian carcinomas [47-
48]. In contrast, the PIK3CB gene which encodes the p110β isoform of the PI3K catalytic domain has 
not been found to be mutated in human cancers. 
 
1.3.3 AKT in cancer 
 
 AKT has been linked to diverse diseases, including diabetes, and neurodegenerative 
disorders [12]. In cancer, AKT activation has been shown to correlate with advanced disease and 
poor prognosis and has three consequences: increased survival via anti-apoptotic signals, increased 
cell proliferation and increased cell growth. Isoform AKT1 is hyperactive in carcinomas, 
glioblastomas and various hematological malignancies. Amplification of AKT1 is frequent in gastric 
[49], prostate, breast and ovary carcinomas [50] and overexpression of AKT has in vitro transforming 
activity [50]. Furthermore it was shown that the gene encoding the AKT2 isoform is amplified in 
breast, ovarian and pancreatic cancers [50-54]. A constitutively membrane bound, phosphorylated 
and active form of AKT has been found in cells from a breast cancer patient, bearing an E17K 
mutation in the PH domain and showing higher levels of activating K63 ubiquitination - as discussed 
later - than wild type [55-56]. Additionally, levels of activated AKT (Ser473 phosphorylation) have 
been found to be increased by 43% in alveolar rhabdomyosarcomas and by 55% in embryonal 
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rhabdomyosarcomas [57]. Table 3 summarizes tumors that commonly show activated AKT. This 
underlines the oncogenic potential of AKT, its central role in disease progression and the importance 
of getting a grip on its aberrant activity in order to inhibit cancer cell proliferation. 
 
Tumor type % tumors with active AKT 
Glioma 55 
Thyroid carcinoma 80 
Breast carcinoma 37,5 
Lung carcinoma 60 
Gastric 80 
Gastrointestinal stromal  30 
Pancreatic carcinoma  50 
Bile duct 85 
Ovarian carcinoma 55 
Endometrial  35 
Prostate 50 
Renal 40 
Large cell Lymphoma 100 
AML 70 
Multiple myeloma 90 
Malignant mesothelioma 65 
Malignant melanoma 55 
Table 3 – Tumors that commonly show aberrant AKT activation. Adapted from Altomare et al. [52] 
 
1.3.4  PDK1 in cancer 
 
 Despite not being a hot spot for alteration itself, PDK1 is the master regulator of the AKT 
oncoprotein and essential for its activation. As discussed, PDK1 is constitutively active and mediates 
one out of two required phosphorylation events to activate the proto-oncoprotein AKT. Thus PDK1 
is located at a crucial position, acting as a switch and providing a rationale to target it in order to 
silence the aberrantly active PI3K/AKT pathway in transformed cells. An example of how PDK1 adds 
to the oncogenic signal is the activating E17K mutation in the AKT PH domain, which is likely to allow 
PDK1 to phosphorylate AKT even in the absence of extracellular stimulus and at low PIP3 levels. The 
role of PDK1 in cancer can therefore be thought of as a constitutively active and essential activator 
of the AKT onco-protein with the potential of being a limiting factor in proliferative signal 
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transduction. Evidence that PDK1 indeed makes for a potentially interesting target comes from 
several studies which suggest its causal role in proliferation and transformation. For example, 
antisense depletion of PDK1 in PTEN-/- glioblastomas reduces cell proliferation in vitro [58] and PDK1 
overexpression in mammary epithelial cells induces their transformation and adhesion independent 
growth in soft agar [59]. PTEN-/- cell progenitors cannot transform or develop into invasive and fatal 
T lymphoma without PDK1 in mice [60], which supports the role of PDK1 as a limiting factor. 
Furthermore, heterozygous PTEN+/- mice, which are normally predisposed to develop PTEN 
deficient tumors through LOH, but expressing reduced PDK1 levels are less likely to develop these 
neoplasms [61]. It has also been suggested that PDK1 is overexpressed and amplified in 20% of 
human breast carcinomas [1, 62]. More recently, it was shown that human cancer cells and breast 
cancer cells with low AKT levels are dependent on the PDK1 substrate SGK for proliferation [63]. 
 
1.4 The ubiquitin system and DUBs  
1.4.1 The post translational modifier Ubiquitin  
 
Ubiquitin is a 76 amino acid (8.5 kDa) small modifier protein present in eukaryotic cells that is 
covalently attached to proteins via an isopeptide bond. It is covalently attached in a three step 
process called ubiquitination that requires activation of the ubiquitin molecule by an activating 
enzyme (E1), transfer of the activated ubiquitin to a conjugating enzyme (E2) and the presence of a 
ubiquitin ligase (E3) that binds the E2 and the target protein and forms an isopeptide bond between 
the ε-amino group of a lysine on the target substrate and the C-terminal glycine 76 (G76) on 
ubiquitin [64]. Ubiquitination can be reversed by de-ubiquitinating enzymes (DUBs) which are 
proteases able to cleave the isopeptide bond between ubiquitin and the covalently bound protein 
[65].  The human proteome comprises two known E1 ubiquitin activating enzymes, approximately 
40 E2 ligases, 600 E3 ligases and approximately 90 DUBs. Ubiquitin itself contains 7 lysines (K6, K11, 
K27, K29, K33, K48, K63) which can be linked to further ubiquitin molecules, thus yielding diverse 
poly-ubiquitin chains with different non-proteolytic roles in the cell.   
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Figure 3 – Ubiquitin conjugation steps. Image taken from Stryer Biochemitry 5th Edition [64] 
 
The synthesis of specifically linked poly-ubiquitin chains seems to depend on the E2 ligase 
catalyzing the reaction or on E2-E3 combinations [66-67]. For example, Cdc34 (E2) generates mainly 
K48-linked poly-ubiquitin, the Mms2/Ubc13 complex (E2) catalyzes the formation of K63 poly-
ubiquitin chains and the APC(E3)/UbcH10(E2) complex forms K11-poly ubiquitin chains [68]. 
Branching poly-ubiquitin polymers using two different lysine residues (e.g. K6 and K11) have also 
been reported [69], yet their physiological function remains unclear. The mono-, oligo- or poly-
ubiquitin epitope on a modified protein can be recognized by at least 20 reported ubiquitin binding 
domains (UBDs) on specific effector proteins and thus affect localization or degradation of the target 
[65]. However the roles of most of the different topologies of the ubiquitin epitopes and the cellular 
mechanisms they control are still poorly understood. The implication of various types of protein 
ubiquitination in cellular processes suggests the notion of a ubiquitin code that regulates protein 
stability, localization and activity.  
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1.4.1 Non-degradative ubiquitination 
 
 The only two well understood types of ubiquitination are the canonical K48-linked poly-
ubiquitin chains which targets conjugated proteins for degradation by the 26S proteasome [70] and 
K63-linked poly-ubiquitination which serves non-degradative roles. K29-linked and K11-linked chains 
also lead to degradation by the proteasome [71-72] or endoplasmatic reticulum associated 
degradation (ERAD) [68]. It is currently not known why different types of poly-ubiquitin chains are 
used for seemingly redundant functions. Non-degradative forms of ubiquitination such as mono-
ubiquitin, multi-mono-ubiquitin - i.e. the attachment of several single ubiquitin molecules on a 
target protein - or poly-ubiquitin chains linked via K63 of an enzyme can affect protein localization, 
recruitment of binding partners in DNA damage repair, inflammation, signal transduction, 
endocytosis and enzymatic activation. An example for K63 dependent activation are TNF-receptor-
associated-factor 2 and 6 (TRAF 2 and TRAF6) which require K63-poly ubiquitination in order to 
further ubiquitinate the inhibitor of IκB complex (IKK), targeting IKK for degradation and thus de-
repressing NFκB transcriptional activity [73]. Furthermore it has recently been shown that the kinase 
AKT is K63-ubiquitinated by E3 ligase TRAF6 and that, upon growth-factor stimulation, this 
modification is important for AKT membrane translocation which enhances AKT activity [55]. Both 
K27 and K33 linkages may be a result of stress response [74] and K6 ubiquitination catalyzed by 
BRCA1 (E3) is involved in DNA repair [75]. The function of mono-ubiquitination, is currently poorly 
explored. Yet there are some examples that hint at different roles that it plays in endocytosis, auto-
inhibition, protein localization and transcriptional regulation. Following ligand binding, EGFR and 
PDGFR are poly-mono-ubiquitinated at the membrane leading to receptor internalization and 
lysosomal degradation, preventing their recycling to the plasma membrane [76]. This mechanism 
allows fine-tuning of receptor activity and is mediated by the endocytic proteins Sts1, Sts2, Eps15 
and Hrs. These regulators of endocytosis are recruited to activated RTKs and bind the mono-
ubiquitinated receptors via their UBA-type UBDs [77]. Recently it has been shown that surface 
receptor ErbB4 is also internalized after mono-ubiquitination by E3 ligase Itch [78]. It has also been 
suggested that mono-ubiquitination is required for cleavage and activation of Notch transcription 
factor by γ-secretase and subsequent downstream signal transduction [79]. Furthermore, in 
mammalian cells, several ion channels undergo internalization in endosomes following mono-
ubiquitination in response to extra cellular signaling [80]. Interestingly, UBDs often mediate mono-
ubiquitination of proteins that contain them [81]. This is the case for Sts1, Sts2, Eps15 and Hrs, 
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which undergo conformational re-arrangement when mono-ubiquitinated, following stimulation of 
RTKs. Their UBD binds their mono-ubiquitinated site in cis, thus inhibiting their own ubiquitin 
binding function in trans [77], in a negative feedback loop that leads to auto-inhibition. Mono-
ubiquitination can also affect the post translational modification state of histones as well as 
transcriptional activity. Nucleosomes are hetero-octamers containing histones H2A, H2B, H3 and H4, 
which are post translationally modified in eukaryotic cells. It was shown that H2B mono-
ubiquitination is required for H3K4 and H3K79 tri-methylation - a transcription de-repressing post 
translational modification - in a process known as histone cross-talk [82]. Furthermore TGF-β 
dependent SMAD4 mono-ubiquitination mediated by p300 was shown to disrupt the SMAD4-
SMAD2 transcription factor complex and lead to relocalization of SMAD4 to the cytoplasm [83]. 
Proteins can be modified by different types of ubiquitination as is illustrated by the differential 
regulation of the tumor suppressor p53, where mono- and poly-ubiquitination serve different roles. 
Mono-ubiquitination on its C terminus exposes a nuclear export sequence which allows p53 to 
relocate to the cytosol whereas K48 poly-ubiquitination of p53 by HDM2 leads to its proteasomal 
degradation [84]. Another example is PTEN, which needs to be mono-ubiquitinated to translocate to 
the nucleus but is degraded upon poly-ubiquitination, which affects its activity as a tumor 
suppressor [85]. 
 
1.4.2 DUBs antagonize E3 ligases 
The process of ubiquitination can be reversed by isopeptidases which hydrolyze the 
isopeptide bonds between ubiquitin and substrate, thus cleaving off ubiquitin moieties. These 
deubiquitinating enzymes (DUBs) can rescue proteins from proteasomal degradation, relocalize 
proteins to sites of activity from which they have been sequestered or revert conformational 
changes that have been induced by ubiquitination [86]. The human genome encodes 79 functional 
proteases with DUB activities, which are cysteine- or metallo-proteases and can be classified into 
five families (Figure 4) [87]. Ubiquitin specific proteases (USP) are the most abundant and contain 
well conserved motifs called cysteine and histidine “boxes” in their catalytic domain. The other 
families are ovarian tumor proteases (OTU), Jamm motif proteases (JAMM), Machado-Joseph 
disease protein domain proteases (MJD) and ubiquitin C-terminal hydrolases (UCH) which are 
thought to play a role in rescuing ubiquitin falsely conjugated to intracellular molecules like 
glutathione or polyamines and to process newly synthesized ubiquitin polymer precursors into 
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single ubiquitin molecules [87]. As opposed to proteases, which are often translated as inactive 
precursors and get activated by post translational modification or changes in pH, DUBs are produced 
as active enzymes [87].  
 
Figure 4 – The five DUB Families.  
 
1.4.3 DUBs can be onco-proteins or tumor suppressors 
  
There is increasing evidence that deregulation of the ubiquitin system can lead to cancer 
[88]. Phosphorylation and ubiquitination are critical in cell proliferation, however ubiquitination 
mediated events are far from being as well understood and documented as phosphorylation. More 
work is required to understand the mechanistic details of ubiquitin dependent regulation of 
important cancer related proteins like AKT, of the catalytic activity, regulation and substrate 
specificity of DUBs, all of which are important for the development of targeted drugs. Since 
ubiquitination is involved in the regulation of many cell signaling processes and cell cycle 
progression in a timed and specific manner, it is assumed that removal of ubiquitin molecules plays 
an equally important role in these processes. Interest in DUBs has grown as they have been reported 
to be mutated in human cancers, supporting their role as oncogenes or tumor suppressors [86], and 
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because they are enzymes which could, if suitable inhibitors are  found, be targets in cancer therapy. 
The DUB TRE2 for instance cleaves ubiquitin from proteasomal degradation remnants and is 
tumorigenic when overexpressed [89]. Another example for the oncogenic potential of DUBs is 
USP9x, which stabilizes MCL1 by deubiquitinating it and preventing its proteasomal degradation, 
thus promoting tumor survival [90]. Of clinical relevance is USP1 which reverses ubiquitination of 
Fanconi Anemia Complementation Group D2 protein (FANCD2), a modification essential for DNA 
damage repair, for maintaining genomic stability and avoiding malignant transformation [91]. 
Fanconi anemia (FA) is characterized by skeletal anomalies, bone marrow failure, cellular 
hypersensitivity to DNA damage and increased incidence of solid tumors and leukemia [91]. In 
normal cells FANCD2 localizes to sites of DNA damage in the nucleus following mono-ubiquitination 
by E3-ligase FANCL, and participates in DNA repair by homologous recombination [92]. Since USP1 
reverses ubiquitination and thus activity of FANCD2, it can be hypothesized that loss of USP1 is a 
reason for hypersensitivity of FA patients to DNA damage and ultimately for malignant 
transformation. Therefore overexpression or hyperactivity of USP1 could promote genomic 
instability and ultimately transformation. Examples of DUBs that act as tumor suppressors are CYLD 
and HAUSP. Patients with familial cylindromatosis carry a mutated or truncated allele of the gene 
encoding CYLD, which predisposes them to develop skin neoplasms [93-94]. In normal cells CYLD 
binds the IKK complex and de-ubiquitinates the adaptor protein TRAF2 thus effectively blocking 
NFκB signaling [95], a process that is deregulated in cells that have undergone LOH for CYLD. A20 is 
another remarkable DUB, as it is both an OTU type DUB for RIP and a Zn finger E3-ligase that 
attaches K48 ubiquitin chains to RIP [96]. DUBs like CYLD, USP6 and A20 can be thought of as true 
oncogenes or tumor suppressors [86]. HAUSP antagonizes the E2-ligase responsible for p53 K48 
poly-ubiquitination and degradation, and thus stabilizes p53 [97]. Currently there is no DUB known 
to act on the K63 poly-ubiquitinated AKT proto-oncogene or mono-ubiquitinated PDK1; however it is 
reasonable to assume that one exists, as ubiquitination is a dynamic and reversible process.  
 
1.5 Therapeutic aspects in cancer 
 
Cancer is a disease characterized by the uncontrolled proliferation of a group of cells that 
metastasize. Cancer therapy therefore focuses on halting or reversing proliferation and metastasis 
formation. Since the 1970s this has been attempted with partial success using chemotherapy and 
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radiotherapy [31]. The aim of these treatments is the killing of rapidly dividing cells by interfering 
with mitosis, while non-dividing tissues in the body are left as unharmed as possible. In 
chemotherapy, cytostatic agents such as DNA alkylating agents which cross-link nucleotides and 
prevent DNA replication, anti-metabolites which stall DNA elongation, topoisomerase inhibitors 
(etoposide, doxorubicin) and DNA damaging agents (cisplatin) have been used. The rationale being 
that cancer cells often lack G2/M checkpoint components (CyclinB/CDK1) and therefore proceed 
into mitosis without repair of DNA damage [31]. Over several days, this results in what has been 
called a mitotic catastrophe, i.e. aneuploidy, accumulating DNA damage, formation of many micro-
nucleoli and eventually cell death driven by apoptosis [98]. These unspecific approaches have 
however many caveats and patients often suffer from adverse side effectssuch as somatitis (mucosa 
inflammation), alopecia (hair loss), nausea, diarrhea, bone marrow suppression (neutropenia, 
thrombocytopenia), nephrotoxcitiy, hepatotoxicity, and neurotoxicity [99]. Over the last thirty years, 
our understanding of the molecular basis of cancer has greatly increased, and it has become 
apparent that cancer is a set of diseases with a highly heterogeneous genetic background [100]. 
Cancer types are no longer classified according to their tissue of origin, but according to their 
genetic profile. This has prompted the search for more targeted therapeutic approaches, which are 
oncoprotein and patient specific. Inhibiting cancer type specific oncogenes could be a way to 
increase efficiency in killing tumor cells, while eliminating the adverse effects of chemotherapy.  
 
1.5.1 Molecular targets in cancer therapy 
 
Efficient relapse free cancer therapy is hampered by the fact that cancer cells have a wide range 
of genetic and epigenetic variation across patients, while exhibiting very little characteristic surface 
markers, which makes them difficult to distinguish from wild-type cells and causes them to respond 
differently to drugs. Despite this high genetic variability, studies in mice [101], human cancer cell 
lines [102] and cancer patients [103-104] have shown that cancer cell survival can sometimes be 
greatly reduced by inhibition of only a single oncogene [105]. For instance, siRNA silencing or 
inhibition of SYK, a tyrosine kinase linked to hematopoietic malignancies, leads to differentiation of 
acute myeloid leukaemia (AML) cells and enhanced survival of mice with AML [106]. Dependence on 
a single oncogene is a phenomenon known as “oncogene addiction” [107] and is sought to be 
exploited in the current development of targeted therapy strategies. This poses two problems for 
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the development of efficient therapies. First, the problem of specificity. At a cellular level, we want 
therapy to stop cancer cells from proliferating, for example by killing them, without harming normal 
cells of the organism. At a molecular level, this generally means inhibiting oncogenic protein as 
specifically as possible without interfering with other proteins, thus avoiding off-target effects, 
which could cause unpredicted and potentially harmful side-effects. Moreover, although a great 
number of altered proteins participating in carcinogenesis are known, only a subset is easily 
targetable. It is generally easier to inhibit an onco-protein, than to restore full function of a defective 
or deleted tumor suppressor. This has established the concept of “druggability” of protein targets. A 
protein is considered to be druggable if it has a well defined function and a catalytic grove in which a 
low molecular weight compound can bind, thus masking several amino acid residues, and leading to 
catalytic inactivation [31]. The problem of specificity must be addressed by developing drugs that 
inhibit druggable targets while remaining harmless for other proteins with similar drug binding 
properties. Second, the problem of delivery. A therapeutic agent usually needs to reach every 
cancer cell to the last in order to achieve complete remission in the patient. Killing off only the bulk 
of cancer cells in a tumor, will eventually lead to relapse after a period of "dormancy" and formation 
of new tumors due to metastases spreading throughout the body which are virtually impossible to 
eradicate with broadband approaches targeting dividing cells only [99]. But the delivery problem 
also extends to more targeted approaches. For instance, many small molecule drugs are prone to 
poor diffusion in solid tumors because of the high interstitial pressure and the resulting sub-optimal 
drug concentrations within the tumor mass [108]. Targeted cancer therapy distinguishes two types 
of drugs used for targeting oncoproteins specifically: macromolecules and small molecule inhibitors 
(molecules smaller than 800 Daltons). Monoclonal antibodies are part of the repertoire of 
macromolecules used to bind cancer antigens that are normally not present in normal cells (e.g. 
fetal antigens) or present in aberrantly high number on the cell surface of transformed cells (e.g. cell 
surface receptors). Trastuzumab (Herceptin) is an antibody against the EGF surface receptor 
HER2/Neu which is overexpressed due to amplification of the Erbb2 gene in a quarter of breast 
cancers [109]. It is one of the earliest examples of targeted therapy and of a drug whose efficiency 
relies on oncogene addiction [107]. The goal of monoclonal antibodies directed against surface 
onco-proteins such as surface receptors, is to stimulate an immune response towards cancer cells or 
inhibit downstream cell cycle activating pathways which are driven by the targeted surface 
receptors (e.g. VEGF, PDGFR, HER2). Small molecule inhibitors on the other hand are used to bind to 
and sterically inhibit mainly intra-cellular onco-proteins. The most promising targets to date are 
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protein kinases involved in signal transduction, such as serine/threonine kinases, cyclin dependent 
kinases (CDKs), DNA damage checkpoint kinases and Aurora kinases [110] due to their involvement 
in cell cycle regulation and their druggability. Kinase activity is relatively easy to inhibit with ATP 
analogues which competitively bind the ATP binding grove. The most widely known example of 
successful targeted therapy by a small molecule inhibitor is imatinib (Gleevec), which inhibits kinase 
activity of the constitutively active fusion protein BCR/ABL, found in of CML patients as the result of 
aberrant recombination of chromosome 9 and chromosome 22 forming the so-called “Philadelphia 
chromosome”. Despite being a breakthrough in treatment of non-solid tumors and making BCR/ABL 
positive CML a manageable condition, the BCR/ABL onco-protein can acquire mutations rendering it 
resistant to imatinib, and leading to relapse in patients. This has been countered by the design of an 
improved imatinib derivative, dasatinib, with inhibitory function against most of the BCR/ABL 
mutants [111]. Other competitive inhibitors have been designed to bind molecular cavities, and 
inhibit functions other than ATP binding. For instance, nutlins block the p53 binding pocket of 
HDM2, thus preventing protein-protein interaction and subsequent p53 degradation. More recently, 
small molecule inhibitors of poly(ADP-ribose) polymerases (PARP) have been developed, which 
compete with NAD+ for binding and inhibit PARP to increase sensitivity to DNA damage from 
alkylating agents [112]. There is a wide variety of possible targets for small molecule inhibitors, so 
we will limit our discussion to the most promising components of the PI3K/AKT pathway and 
selected examples of the ubiquitin system as they are most relevant here. 
 
1.5.1.1 Targeting the PI3K/AKT pathway 
1.5.1.1.1 Targeting PI3K 
 
 Wortmannin and LY294002 both inhibit PI3K however they are isoform unspecific and have 
shown toxicity in animals [113]. In fact, broad spectrum PI3K inhibition is likely to result in high 
cytotoxicity due to involvement of PI3K in many cellular processes. For instance, the p110α isoform 
of the PI3K catalytic subunit is largely attributed to functions such as insulin signal transduction and 
AKT activation [114]. The p110β isoform was thought to have redundant function to p110α but it 
was shown that p110α and p110β seem to have distinct roles in cellular activity. Although involved 
in metabolic pathways, p110β plays a role in inflammation, vascular trafficking [115] and platelet 
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formation [116]. Furthermore, cells of the immune system are more dependent on the p110γ and 
p110δ isoforms rather than p110α [117]. Thus targeting the p110α isoform specifically could impede 
tumor cell growth with reduced toxicity to the immune system. It is therefore desirable to achieve 
isoform specificity with inhibitors, as this may help reduce unwanted side effects, and so, more 
specific inhibitors are being developed and are currently in phase I and II clinical trials. PI-103 for 
example inhibits the p110α subunit of PI3K which is essential for insulin signaling, and also inhibits 
mTOR as a convenient off target effect [118]. In fact, dual target PI3K inhibitors are currently 
entering clinical Phase I trials. Another example for such an inhibitor is BEZ235 that inhibits class I 
PI3K isoforms and mTOR by binding to the ATP‑binding grove [119]. 
 
 
Figure 5 – Target nodes of the PI3K pathway with examples of drugs in use or in clinical development. 
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1.5.1.1.2 Targeting mTOR 
 
 Mammalian target of rapamycin (mTOR) is a serine/threonine kinase that exists in the form 
of two complexes: mTORC1 and mTORC2. mTORC1 can be activated by AKT and acts on p70S6K and 
4EBP1 to promote protein synthesis while mTORC2 phosphorylates AKT on Ser473 and leads to its 
activation [1]. Rapamycin was the first inhibitor for mTORC1 and rapamycin analogues temsirolimus 
and everolimus have since been developed, with better pharmacological properties [120]. They have 
improved survival in patients with renal carcinoma, but low response rate in patients with breast 
cancer and glioma [121]. More recently the ATP competitors torkinib and torin 1 have been shown 
to inhibit both mTORC1 and mTORC2, and thus block the PI3K pathway more efficiently [1]. 
 
1.5.1.1.3 Targeting AKT 
  
 Inhibiting AKT, because of its role in cell proliferation, growth and anti-apoptotic signaling 
could impede tumor growth by induction of apoptosis or by sensitizing tumors to cytotoxic agents. A 
variety of agents have been successfully used to inhibit AKT in vitro and in vivo. These include small 
molecule ATP competitive inhibitors (e.g. GSK690693, in phase I clinical trials [1]), allosteric 
inhibitors (e.g. AKTi-1, AKTi-2 and MK2206 show isoform specificity for AKT1 and AKT2 and are 
currently in phase I against metastatic solid tumors [1]), phosphoinositide (PI) analogs aiming at 
inhibiting the AKT PH domain (e.g. PX316 in phase I and perifosine currently in phase II have shown 
inhibitory effects in tumors with high AKT activity [122]), single chain variable fragment synthetic 
antibodies (scFv) and pseudosubstrates (e.g. 14-mer peptide AKTide-2T which binds to the substrate 
binding site of the AKT1 isoform [123]) [124]. Despite partially promising results in patients, none of 
the compounds discussed above have completed clinical trials or have achieved complete remission 
in patients to this day, thus justifying the search for an alternative approach. 
 
1.5.1.1.4 Targeting PDK1  
 
 The attractiveness of PDK1 as a potential anticancer target is linked to its ability to 
phosphorylate and activate a diverse set of AGC kinase members, in particular the AKT isoform 1. 
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But despite its importance as an essential activator of AKT, only few studies have considered PDK1 
as a potential target for cancer therapy compared with studies of AKT1. Yet there is evidence that 
PDK1 inhibition can sensitize cells for treatment with cytostatic drugs more efficiently than 
inhibition of other members of the pathway and may thus be an interesting target. Tamoxifen is a 
prodrug that is metabolized into 4-hydroxy-tamoxifen in the liver and competes with estrogen for 
estrogen receptor (ER) binding [125]. It is one of the most used small molecule drugs against 
ER positive breast cancers, but tumors can become resistant, which leads to relapse in metastatic 
and some non-metastatic patients. It has been reported that RNAi mediated PDK1 knock down 
sensitizes MCF7 breast cancer cells to tamoxifen and to ICI 182780 in vitro, a drug that leads to ER 
degradation [126]. Furthermore, mouse mammary cells overexpressing PDK1 are more resistant to 
gemcitabine than cells overexpressing AKT, and human breast cancer cells are rendered more 
resistant to gemcitabine treatment if they have high levels of phosphorylated PDK1 as compared to 
high levels of phosphorylated AKT [127]. PDK1 knock down in PTEN defective glioblastoma cells 
reduces levels of activated AKT and inhibition of cell proliferation in vitro [58]. The fact that the 
allosteric AKT inhibitors Akti-1 and Akti-2, which rely on preventing AKT phosphorylation by PDK1, 
have shown success and are in clinical trials [128-129] also argues for PDK1 as a master activator and 
important target. Thus, PDK1 may be a superior inhibition target to AKT for sensitizing cells to 
treatment with cytostatic drugs like gemcitabine. Targeting PDK1 and thus indirectly curbing AKT 
activity may also help reducing selective pressure on tumors and thus reduce tumor resistance in 
transformed cells with oncogenic AKT, as opposed to targeting AKT directly. In addition, the fact that 
PDK1 hypomorphic mice expressing low levels of PDK1 are viable suggests that PDK1 inhibition could 
suffer less from side effects and toxicity [119]. Several classes of structurally diverse PDK1 inhibitors, 
including tetracyclics, tricyclics, azaindoles, indazoles, and indenylpyrazoles have already been 
identified [130]. UCN-01 is a staurosporine derivative kinase inhibitor which inhibits PDK1 activity 
with an IC50=5nM [131] and is currently in phase I clinical trials with good results [119] but UCN-01 is 
a non-specific kinase inhibitor, which has the drawback of being prone to off target effects. A caveat 
of inhibiting the PI3K/AKT pathway, is that it can cause insulin resistance - insensitivity to insulin 
signals - in normal cells and lead to weight loss, increased blood sugar levels and even type 2 
diabetes [119]. BX320 and BX517 are ATP competitive binders that inhibit PDK1 with better 
selectivity than UCN-01 and are also currently in clinical trials [119]. Celecoxib can block AKT 
activation in several cancers by inhibiting PDK1 kinase activity with IC50=30µM [132] and is currently 
in phase II/III trials as a single compound or in combination with others [119]. OSU-03012 is a 
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derivative of celecoxib based on structural design optimization with slightly better anti-proliferative 
activity [133]. PHT-427 is a PH domain inhibitor originally designed to inhibit AKT PH domain but 
which was reported to also inhibit the PH domain of PDK1 and lead to reduction in xenograft size 
with minimal toxicity [134]. 
 
 
Figure 6 – Small molecule inhibitors of PDK1. Adapted from Garcia-Echeverria et al. 2008 [119] 
 
1.5.1.2 Targeting the ubiquitin system 
 
The ubiquitin system is involved in regulation of stability, localization and activity of many 
proteins by proteolytic and non-proteolytic ubiquitination and thus plays an indirect role in 
controlling cancer relevant cellular mechanisms like cell cycle and apoptosis. Therefore interfering 
with the ubiquitination state of cancer relevant proteins is considered a possible new strategy for 
cancer therapy.  
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1.5.1.2.1 Proteasome 
 
 Although proteasome malfunction itself has not been linked to cancer, it is considered a 
target for inhibition. The most prominent example being bortezomib (Velcade), a small molecule 
inhibitor of the active sites of the 20s proteasome [135]. This prevents degradation of IκB, a negative 
regulator of the proliferation promoting transcription factor NFκB. p53 is also stabilized by 
bortezomib because it cannot be degraded following poly-ubiquitination by HDM2. New 
proteasome inhibitors like carfilzomib, NPI-0052, CEP-18770 and argyrin A aim at blocking the 
proteasome in a pathway dependent manner [136]. For instance, NPI-0052 is dependent on FADD-
Caspase8 cell death signaling for inhibition [137].  
 
1.5.1.2.2 E3 ligases  
 
 Inhibiting the active site of ubiquitin ligases was initially thought to be a strategy to 
selectively inhibit them [136]. For example, Inhibiting overactive HDM2 could be a way of restoring 
p53 activity in tumors or inhibiting SKP2, a member of the SCF ligase complex responsible for 
ubiquitin dependent p21 and p27 degradation [138-139] could prevent G1-S transition in tumors 
with low p27. Another example is inhibition of E3-ligase TRAF6 in tumors with high AKT activity, as 
TRAF6 depleted cells with overactive AKT injected into mice have reduced tumorigenic potential 
[55]. Nutlins were the first drugs designed to competitively inhibit activity of a specific E3-ligase, by 
blocking the substrate binding grove of HDM2, and thus preventing it from ubiquitinating p53 and 
targeting it for degradation [140]. But nutlins have the caveat of requiring a wild type copy of p53 to 
be present in the cancer cell. Additionally, nutlins have off-target effects, as shown by their ability to 
induce cell cycle arrest despite a p53-/- background, in lung carcinoma cells [141]. The reverse 
strategy of inhibiting substrates of E3 ligases, for instance with the small molecular inhibitor RITA 
targeting p53 and preventing its association with HDM2, suffer from low specificity [142]. Enhancing 
E3 ligase activity on the other hand, despite being a much more challenging approach, could 
potentially be the more interesting one. For instance, enhancing Fbxwd7 and pVHL activity using 
agonists rather than inhibitors, would improve inhibition of cyclin E and HIF1a respectively, 
preventing cell proliferation and tumor vascularization. Unfortunately none of these approaches 
have so far yielded any satisfying results in terms of specificity and off target effects.  
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1.5.1.2.3 DUBs 
 
 The role of DUBs in regulating many cell cycle relevant processes makes them potential 
targets for therapy. However there are currently no active compounds being clinically used as drugs 
that selectively act on them. But examples exist showing that in principle DUBs can be targeted in 
cancer. One such example is UCH-L1, a DUB that has been linked to Parkinson's disease [143-144] 
and cancer as it is expressed in many primary lung tumors but is absent from normal lung tissue 
[145]. A small molecule inhibitor (an o-acyl oxime derivative of isatins) against UCH-L1 has been 
shown to selectively kill tumor cells in vitro [146-147]. However, much better understanding of DUB 
catalytic activity, regulation and substrate specificity, as well as large scale mapping of DUB 
substrates will be required before DUB inhibitors or agonists will enter clinical use. 
2 Results 
 
We have discussed the involvement of the PI3K/AKT pathway in cancer as well as the 
importance of the ubiquitin system as a regulator of cellular processes and as a therapy target. Here 
we show that PDK1, a kinase crucial for AKT activation in normal and transformed cells, is 
endogenously mono-ubiquitinated and perform experiments to better characterize this post 
translational modification. We attempt to map the site of ubiquitination on PDK1, to identify a DUB 
that reverses this conjugation and to describe possible functional roles of PDK1 ubiquitination. 
Identifying the site, role and interactors responsible for PDK1 ubiquitination will lead to a better 
understanding of PDK1 activity and its regulation and may yield a potential new therapeutic target 
upstream of AKT, in cancers with an overactive PI3K/AKT pathway.  
 
2.1 PDK1 is mono-ubiquitinated 
 
 While performing an unrelated screen for DUBs, we have serendipitously observed a 
western blot signal suggesting that PDK1 may be conjugated to a ubiquitin-like modifier (Ubl) 
when ubiquitin was overexpressed. The main downstream target of PDK1, the serine/threonine 
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kinase AKT, has been shown to be K63 poly-ubiquitinated, a process required for its translocation 
to the plasma membrane (PM) and subsequent activation [55]. Ubiquitination of PDK1 on the 
other hand has not been described to our knowledge, but could potentially play a role in PDK1 
regulation. In order to establish whether this post translational modification occurred 
endogenously, we immunoprecipitated endogenous PDK1 without overexpressing ubiquitin. As 
control an IgG antibody was used. Immunoprecipitation of endogenous PDK1 in HEK293T cells 
reproducibly co-precipitated a band running approximately 10kDa higher than endogenous PDK1, 
at the predicted height of mono-ubiquitinated PDK1 (Figure 7a). We were able to reproduce this 
result in the U2OS osteosarcoma cell line (Figure 7b). When overexpressing His-tagged PDK1 and 
affinity purifying it, we could enrich for both the PDK1 and ubiquitinated PDK1 forms (Figure 7c). 
The same holds true when only ubiquitin is overexpressed in HEK293 cells, where we observed an 
increase in the signal intensity of the ubiquitinated form of PDK1 (Figure 7d). Three isoforms of 
PDK1 exist – isoforms 2 and 3 are catalytically inactive - but interestingly we observed only one 
PDK1-ubiquitin band approximately 10kDa above the triple PDK1 signal, suggesting that only the 
largest PDK1 isoform is ubiquitinated in HEK293T and U2OS cell lines. Furthermore we were able 
to immunoprecipitate mono-ubiquitinated PDK1 in 6 out of 9 tested cell lines with no PDK1 or 
ubiquitin overexpressed (Figure 7e). These data suggest that endogenous PDK1 is indeed mono-
ubiquitinated. We therefore wanted to further characterize this post translational modification by 
identifying the site of conjugation and elucidate the cellular function of PDK1 mono-ubiquitination. 
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Figure 7 – PDK1 is mono-ubiquitinated. 
a. Western blot showing endogenous PDK1 signal following PDK1 IP in HEK293T cells using PDK1 antibody only (lane 
1), sepharose beads only (lane 2), igG2a control antibody with beads (lane 3) or PDK1 antibody with beads (lane 4). b. 
Western blot showing endogenous PDK1 signal following PDK1 IP in U2OS cells using IgG2a control antibody (lane 1) 
or PDK1 antibody (lane 2) c. Western blot showing PDK1 signal following His AP from untransfected HEK293T or 
HEK293T transfected with His-V5 tagged PDK1. d. Western blot showing PDK1 signal following His AP from 
untransfected HEK293T or HEK293T transfected with His- tagged ubiquitin. e. Western blot showing endogenous 
PDK1 signal following PDK1 IP from various cell lines. HEK293T (human embryonic kidney cells), HEP1 (human 
hepatoma), HeLa (human cervix carcinoma), K562 (human AML), U2OS (human osteocarcinoma), A2780 (human 
ovarian carcinoma), Hacat (human keratinocytes), A549 (alveolar basal epithelial carcinoma), MEF (mouse embryonic 
fibroblasts). 
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2.2 Mapping of PDK1 mono-ubiquitination 
 
 Mono-ubiquitination is known to regulate processes like translocation from the nucleus to 
the cytoplasm of transcription factors or endocytosis of membrane bound receptors and could 
therefore be a previously undescribed regulating modification of PDK1. PDK1 contains 38 lysine 
residues, each of which could potentially form an isopeptide bond with G76 on the ubiquitin 
molecule. Inter-species sequence comparison of PDK1 using the ClustalW algorithm shows that 12 of 
these lysines are conserved (Figure 8).  
 
 
 
Figure 8 – Inter species sequence alignment of PDK1. 
Alignment was done using the ClustalW algorithm in mouse, rat, human and fruit fly. Sequence information was obtained 
from UniProt. Lysine residues are highlighted in yellow. Lysines were counted as conserved when they were present in all 
four organisms. 
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Figure 9 – Mapping the mono-ubiquitinated lysine residue. 
 a. Mutated conserved lysine residues of PDK1. Western blot showing PDK1 signal from HEK293T cells overexpressing PDK1 
lysine mutants. GFP is co-transfected as transfection control. b. Truncation mutants of PDK1 (top), showing only the lysines 
(green) and agarose gel picture of truncated PDK1 PCR products prior to ligation into expression vectors. c. Whole cell 
lysate from HEK293T cells transfected with expression vectors encoding the PDK1 C and N terminal truncations. d. Western 
blot V5 (PDK1) and Flag (PDK1) signals after affinity purification of overexpressed truncations from HEK293T cells. e. 
Western blot showing PDK1 signal after Flag-ubiquitin affinity purification from HEK293T cells overexpressing truncations 1 
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and 2 and Flag-ubiquitin (lane 1 and 2). V5 signal (PDK1-Ub) from HEK293T cells transfected with truncations 3-8 and full 
length (FL) V5 tagged PDK1 and Flag-ubiquitin (lane 3-9). f. Western blot showing V5 signal (PDK1-Ub) from HEK293T cells 
transfected with truncations 3-7 V5 tagged PDK1 and Flag-ubiquitin. g. WCL western blot showing V5 signal from HEK293T 
cells ectopically expressing PDK1wt and PDK1 kinase domain (KiDom). 
____________________________________________________________________________________________________ 
 
 We hypothesized that if mono-ubiquitination is involved in regulating PDK1, this post 
translational modification is likely to be present in different species and therefore possibly located 
at a conserved lysine residue. We proceeded to mutate 12 conserved lysines to arginines 
individually and to screen for a loss of ubiquitination signal. Arginines, while having similar 
electrostatic properties as lysine (basic side chain), are not ubiquitin acceptor sites, and thus 
substitution prevents ubiquitination while minimizing disruption of protein folding or charge 
repartition. For lysines #293, #296 and #492, #494 which are located close together, we created 
double mutants to eliminate the possibility of these mutants being ubiquitinated at either residue 
randomly, thus effectively cutting down the number of total mutants to 10. PDK1 mutants were 
transfected in HEK293T cells and whole cell lysates were analyzed by western blot. Membranes 
were probed with anti-PDK1 antibody. None of the mutants showed a loss of ubiquitination signal, 
suggesting that despite being conserved, none of these residues are ubiquitinated in HEK293T cells. 
The K441R and K465R/K467R mutants seemed to show a loss of mono-ubiquitin signal, however 
they also show a weaker total PDK1 signal indicating that these mutants are not stable in the cell 
(Figure 9a). It is therefore unlikely that the loss of upper band signal in these mutants is due to a loss 
in mono-ubiquitination. As an alternative approach we created C and N terminal truncation mutants 
of PDK1 (Figure 9b), reasoning that eliminating lysines successively and screen for a loss of 
ubiquitination would allow us to narrow down the ubiquitin-conjugated lysine residue. The C-
terminal and N-terminal truncation mutants were Flag and His-V5 tagged respectively, transfected in 
HEK293T cells and immunoprecipitated. Both C-terminal truncations were expressed, detectable 
and showed ubiquitination signal (Figure 9c). Of the N-terminal truncations, only the truncations #3, 
#5, #6 and #7 seemed to be stably expressed and detectable after pull down (Figure 9d). For reasons 
we could not determine, a ubiquitination signal could not be detected for these truncations except 
for the smallest truncation #7. We next co-overexpressed Flag-tagged ubiquitin with the truncations 
in HEK293T cells, immunoprecipitated with Flag antibody and probed for V5 tagged PDK1 (Figure 
9e). We reasoned that overexpressing ubiquitin increases ubiquitin signal and may facilitate 
detection of ubiquitination on PDK1 truncations or the absence thereof. However we could only 
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detect full length PDK1 and N-terminal truncations #3, #5 and #7. Again, truncation #7 seemed to be 
ubiquitinated, despite lacking 24 of the N-terminal lysines and despite the fact that longer 
truncations did not appear ubiquitinated. These results do not allow a clear conclusion on the 
modified site on PDK1. Since truncation mutants containing large parts of PDK1 domains seemed 
unstable in the cell, we decided to try an alternative truncation approach, by overexpressing only 
the intact His tagged kinase domain or the intact PH domain in HEK293T cells. We reasoned that if 
domain integrity is a criterion for peptide stability, full length domains expressed separately should 
be more likely to be stable than mutants containing partial domains. The kinase domain however 
was stably expressed and showed ubiquitination signal after affinity purification (Figure 9f) yet the 
PH domain alone was not stably expressed. Although the lack of an expressed PH domain as control 
does not allow us to conclude with absolute certainty that PDK1 is ubiquitinated in the kinase 
domain, this result hints at the fact that it may be the case.  We conclude that the modified lysine 
residue can be narrowed down with reasonable probability to one of the 27 lysines of the kinase 
domain. In order to improve mapping accuracy we next applied a tandem affinity purification/mass 
spectrometry (TAP-MS) approach.  
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2.3 Affinity purification and LC-ESI-MS/MS 
 
 As opposed to truncation experiments, mass spectrometry (MS) is a more powerful tool that 
offers the potential to pin-point the ubiquitinated lysine by identifying the m/z fingerprint of a 
peptide conjugated to a double glycine remnant (GG). Finding the ubiquitinated lysine is crucial 
since it will allow us to investigate the role of PDK1 mono-ubiquitination in a targeted manner. As a 
proof of principle, we analyzed highly purified di-ubiquitin by LC-ESI-MS/MS and were able to detect 
ubiquitin and the attached GG remnant (data not shown); indicating that in principle mono-
ubiquitination and its site of conjugation can be detected. However, the bottleneck to a conclusive 
MS result when analyzing complex mixtures such as whole cell lysates is the preliminary step of 
affinity purification. The ubiquitinated protein must be purified as stringently as possible to avoid 
contamination by other peptides and thus reduce noise in subsequent fragment ion detection. In 
order to find an affinity purification protocol that would allow us to efficiently purify the 
ubiquitinated form of PDK1, we chose to use three different approaches to isolate ubiquitinated 
PDK1 from whole cell lysate (Figure 10). Samples from all three affinity purification approaches were 
verified via western blot, to assess whether they could be used for silver staining, band excision, in 
gel tryptic digestion and mass spectrometry analysis. In our first approach (Figure 10a) we created a 
plasmid vector to overexpress His-tagged PDK1 in HEK293T cells, which we affinity purified with Ni 
coated agarose beads, and were able to detect in its ubiquitinated form in the eluate via western 
blot (Figure 11a). Unfortunately this approach did not allow a clear detection and excision of the 
PDK1-Ubiquitin band by silver stain. This may be due to the lack of specificity of the approach. 
Western blot allows very specific detection of proteins in complex mixtures by use of specific 
antibodies, but whole protein staining methods like silver staining require a much higher level of 
preliminary separation to unambiguously visualize individual bands of interest. 
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Figure 10 – Affinity purification (AP) approaches to isolate PDK1-Ubiquitin for MS/MS. 
a. His-tagged PDK1 is transfecfted in HEK293T cells for AP. b. Protein G and Myc tagged PDK1 is retrovirally introduced 
(infection) in HEK293T cells. Cells are then transfected with His or HA tagged ubiquitin before AP. Panel on the right is 
western blot showing Myc signal from cells infected and uninfected with retrovirus vector. c. Flp-In™ T-REx™ 293 Cells 
were flip recombined with PDK1-SH construct to create HEK293TSH cell line expressing PDK1-SH in a Dox inducible 
manner. AP was then done using a two step approach (Strep-tactin coated beads followed by HA-IP) or a three step 
approach using Strep-Tactin/HA/Flag AP. 
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Figure 11 – Affinity purification of ubiquitinated PDK1 and silver staining. 
a. Western blot PDK1 signal from the first AP approach. Cells are transfected with His tagged PDK1 and AP is done with Ni-
coated beads with affinity to the His-tag. WCL, whole cell lysate, Untransf, untransfected control cells. b. PDK1 signal from 
TAP followed by TEV cleavage. First AP is an immunoprecipitation of HA-tagged ubiquitin. Second AP is an 
immunoprecipitation of Protein G. Lane 1 and 2 show PDK1 signal from the WCL before and after HA immunoprecipitation. 
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Lane 3 shows cleaved PDK1 band running lower due to the loss of its protein G tag. Lane 4 is the PDK1 signal from boiled 
HA-antibody coated beads after TEV cleavage. c. Western blot PDK1 signal from second TAP approach. First step is a His AP 
followed by immunoprecipitation of Protein G d. Western blot HA (PDK1) and Flag (Ub-PDK1) signals from Triple-AP in 
HEK293TSH cells transfected with Flag-Ub. First step is a StrepIII AP (for PDK1), followed HA IP (for PDK1) and Flag IP (for 
ubiquitin). e. Western blot HA (PDK1) signal from Strep-HA AP in HEK293TSH cells overexpressing ubiquitin. f. Silver stain 
gel of lane 9 from (e). Bands A05 (PDK1-ub) and A06 (PDK1) were excised and analyzed by LC-ESI-MS/MS. 
_________________________________________________________________________________________________ 
  
To increase pull down specificity we therefore chose a two-step protocol next. Tandem 
affinity purification (TAP) is a protocol that has been used to isolate proteins and protein complexes 
for subsequent MS analysis [148] and should therefore be usable for isolation of ubiquitinated PDK1 
for MS. In our second approach (Figure 10b) we cloned wild type PDK1 in a TAP vector, under the 
control of a strong promotor (CMV), in frame with a myc tag, a tobacco etch virus cleavage 
sequence (TEV), which can selectively be cleaved by a TEV protease (Nuclear Inclusion A protein 
"NIa"), and a protein G sequence. The PDK1-proteinG construct was stably expressed in HEK293T 
cells after transduction with a retroviral vector and 72h puromycin selection. We refer to this cell 
line as HEK-TAP. We then transfected HEK-TAP cells with His or hemagglutinin (HA) tagged ubiquitin.  
The ubiquitinated fraction of the lysate was then enriched by nickel-affinity purification or using 
antibody against the HA epitope. In a second step we immunoprecipitated PDK1 from the 
ubiquitinated fraction with an anti-proteinG antibody. HA/IgG purification allowed PDK1 isolation 
and subsequent TEV cleavage mediated elution also worked as indicated by the PDK1-Ub band 
running lower than non-ubiquitinated PDK1 (Figure 11b). However not enough material could be 
isolated by this method and no PDK1 or ubiquitin peptides were detected by mass spectrometry. 
Loading the eluted anti-HA antibody coated agarose beads to control for the quality of elution 
revealed that significant amounts of PDK1 are seemingly aspecifically attached to the beads. 
Additionally, as lane 2 and 3 suggest, depletion of PDK1 was not efficient. Whole cell lysate (WCL) 
after anti-HA AP still shows a strong PDK1 signal and the cleaved PDK1-Ubiquitin is faint. Repeating 
the experiment with a different lysis buffer did not resolve the problem. Replacing the HA 
immunoprecipitation step by a Ni/His AP (Figure 11c) allowed us to precipitate PDK1 in good 
amounts but at the cost of specificity, as the isolate did not reveal clean excisable bands after silver 
staining. As a third approach (Figure 10) we decided to use alternative affinity tags, in order to 
circumvent the specificity problem while obtaining good enrichment for PDK1-Ubiquitin. To this end 
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a Flip-in recombination system was used to create a cell line (HEK293TSH) stably and inducibly 
expressing StrepIII-HA-tagged PDK1. This system has been developed based on standard TAP 
protocols to increase throughput and yield in large scale proteomics studies [149]. The advantage of 
this approach is that PDK1 is stably expressed at comparable rates in different experiments after 
doxycycline induction, allows culture of cells in larger amounts for lysis and that the StrepIII-tag 
interacts strongly with the streptavidin derivative Strep-tactin [150]. We cloned PDK1 wild type 
cDNA sequence into an expression vector containing StrepIII and HA sequences using the gateway 
cloning system, which was co-transfected into HEK293 cells with a plasmid expressing Flip-
recombinase. Cells were then transfected with Flag-ubiquitin or left untransfected. Affinity 
purification was done, in one case, using strep-tactin sepharose followed by immunoprecipitation 
with HA antibody - thus isolating PDK1 in its ubiquitinated and unubiquitinated form - and 
subsequent immunoprecipitation with Flag antibody to purify the ubiquitinated fraction of PDK1 
from this pool. In the other case, we only precipitated with Strep-tactin and HA antibody, relying on 
PAGE for separation of unmodified and ubiquitin-conjugated PDK1. The signal from ubiquitinated 
PDK1 was lost in the StrepIII/HA/Flag after the HA immunoprecipitation step, and PDK1 signal was 
lost following Flag immunoprecipitation (Figure 11d). It is unclear why the ubiquitinated PDK1 signal 
was lost after HA precipitation, but it could be due to the insufficient amount of biological starting 
material. When we repeated the last experiment with double the amount of cells and without Flag 
immunoprecipitation, we were able to isolate both PDK1 and ubiquitinated PDK1 (Figure 11e). 
Elution however was not optimal, as can be seen when comparing lane 8 and lane 9, where boiled 
HA beads gave a stronger PDK1 signal than the eluate. However the overall purification using this 
protocol returned a silver stain signal that was clean enough for band excision and subsequent MS 
analysis. Bands A05 and A06 were excised (Figure 11f), digested in gel with trypsin and analyzed by 
LC-ESI-MS/MS. A05 is predicted to be the ubiquitinated form of ubiquitin and A06 unmodified PDK1. 
Figure 12 shows the MASCOT readout of the database matched fragment peptides, from two MS 
runs of each digest, respectively using inclusion list 1 or list 2. The inclusion lists include predicted 
fragment ions of PDK1, with priority on fragment ions resulting from tryptic cleavage C-terminally of 
lysines rather than arginines. PDK1 was detected in A05 and A06 and ubiquitin was detected in A05 
with both inclusion lists and in A06 with only one inclusion list. Detection of ubiquitin alone is a good 
indicator that affinity purification worked and further supports our finding that PDK1 is 
ubiquitinated, but does not allow to conclude on the ubiquitination site of PDK1. In fact, no m/z 
fingerprint of GG-coupled PDK1 was detected and thus it is not possible to conclude where the 
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ubiquitin signal stems from or what lysine residue is conjugated to the GG remnant. It may also be 
that the predicted m/z for GG-bound PDK1 was not detected due to low sequence coverage (highest 
sequence coverage was 44% for PDK1 and 50% for ubiquitin). If the GG-remnant lies outside the 
covered sequence, it is not detected in this analysis, requiring more replicates of this assay to be 
run. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 45 
 
 
 
Figure 12 – MASCOT readout from MS/MS analysis of A05 and A06 trypsin digested bands. 
Top panel, A05. Bottom panel, A06. S.C., sequence coverage. The left side of each panel shows the MASCOT raw data for 
potentially identified proteins according to peptide fingerprints. The right side (red) shows peptides that were matches for 
PDK1 (top) and ubiquitin (bottom). 
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2.4 Loss of function RNAi screen for a DUB acting on PDK1 
 
 We proceeded to screen two libraries of DUBs for a deubiquitinase that would act on PDK1 
and reverse its ubiquitination. Identifying interactors of PDK1 that might play a role in its post 
translational modification - DUBs specifically - may shed light on the role of PDK1 mono-
ubiquitination. Additionally, on the background of therapeutically targeting PDK1 in cancers, a DUB 
could provide a new angle of attack. To perform the loss of function RNAi screen we used a shRNA 
library mediating stable RNA interference against 50 known DUBs established by T.R. Brummelkamp 
and S.M. Nijman [95] and an siRNA Smart pool library by Dharmacon targeting 100 genes. The 
shRNA library consists of the pSUPER vector system, where each vector encodes a synthetic 19bp 
oligonucleotide under the control of the mammalian RNA Pol III promoter. The shRNA library we 
used contains pools of 4 knock down vectors against each targeted DUB for increased knock down 
efficiency. Functionality of this library was verified by RT-PCR for the shCYLD and shUSP1 constructs 
(Figure 13c) and by western blot (Figure 13e). Functionality of the Dharmacon siRNA library was 
verified by RT-PCR for the USP3, USP32, USP5, USP7 and USP9x constructs (Figure 13d). HEKTAP cells 
were seeded in 6 well plates and each well transfected with GFP as a transfection control and a 
siRNA or shRNA knockdown vector pool directed against one specific DUB. Two days after 
transfection cells were lysed, protein G tagged PDK1 was immunoprecipitated using anti-G antibody, 
analyzed by PAGE and western blot and the precipitate was monitored for an increase in the PDK1-
ubiquitin signal (Figure 13a). An increase in the ubiquitinated form of PDK1 would suggest that the 
knocked-down DUB normally acts on PDK1 to deubiquitinate it. A representative example of a 
western blot read-out is given in (Figure 13b). However no significant increase in the ubiquitinated 
fraction was detected and thus no DUB was identified for PDK1. 
 47 
 
  
Figure 13 – Loss of function screen for a DUB acting on PDK1. 
a. Workflow of loss of function DUB screen. HEK293T cells are infected with a retroviral vector with Protein-G tagged 
PDK1. Cells are then transfected with shRNA or siRNA libraries against DUBs, and lysates are screened by Western blot b. 
Example of western blot screen showing PDK1 signal after protein G (PDK1) IP from HEKTAP cells transfected with DUB 
knock-down library. c. RT-PCR for CYLD and USP1, in untransfected cells (control) and cells transfected with shRNA. d. RT-
PCR for USP3, USP32, USP5, USP7 and USP9x in untransfected cells (control) and cells transfected with siRNA. Three 
technical replicates. e. Western blot from cells untransfected, transfected with random shRNA and shRNA against CYLD. 
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2.5 Functional characterization of PDK1 mono-ubiquitination 
 
 Understanding the functional role of PDK1 ubiquitination could yield important insight into 
its role in regulating PDK1 activity, which may also be used to target PDK1 therapeutically. More 
work is needed to identify the lysine residue that is modified by ubiquitin and until this information 
is available it is difficult to accurately generate PDK1 mutants lacking ubiquitination or 
physiologically correct PDK1-ubiquitin fusion mutants, which are essential to further study the 
function of ubiquitination. Despite lacking this knowledge, we can nevertheless perform 
experiments that will give an idea of the role of ubiquitination. We first investigated if attachment of 
a mono-ubiquitin influenced PDK1 localization. Although to our knowledge there are no cytoplasmic 
kinases known to relocalize upon mono-ubiquitination, examples exist of other proteins such as the 
transcription factor p53 which relocalize to the cytoplasm upon mono-ubiquitination. We created a 
V5 tagged PDK1-ubiquitin fusion protein which we expressed in U2OS cells. We then performed 
immunostaining with an anti-V5 antibody and a fluorescently labeled secondary antibody, which 
was analyzed by confocal laser microscopy. Transfection efficiency was controlled by co-transfecting 
GFP and detection efficiency of our construct was controlled by transfecting V5-labelled PDK1 with 
no ubiquitin fusion. The fluorescence levels of the PDK1-V5-Ub fusion and PDK1-V5 were 
comparable, as were transfection levels. We did however not observe any differences in localization 
to the plasma membrane or the cytoplasm between the two constructs (Figure 14a). Our 
observation suggests that this type of ubiquitination does not influence localization of PDK1. 
Ubiquitin binding domains on effector proteins, which are responsible for recognition of 
ubiquitinated proteins are diverse and specific to different types of ubiquitination [81]. We can 
therefore not exclude the possibility that the artificial PDK1-Ubiquitin fusion does not accurately 
represent the normal physiological setup within the cell. The PDK1-ubiquitin fusion may not be 
recognized by the normal effectors and may thus not show a different repartition within the cell 
than the control. To circumvent the problem of an artificial PDK1-ubiqutin fusion, we next 
fractionated the cell lysate from HEK293T cells transfected with PDK1-V5, and immunoprecipitated 
PDK1-V5 with a V5 antibody. PDK1 was found in all three fractions (cytoplasmic, membrane and 
nuclear), as was the ubiquitinated form of PDK1 (Figure 14b). This suggests once more that mono-
ubiquitinated PDK1 does not show a preference for localization to either one of these cellular 
compartments. Since we haven't found mono-ubiquitin to influence localization so far, we wanted 
to investigate whether it played a role in pathway activation. The PI3K/AKT pathway is involved in 
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insulin signaling, leading to phosphorylation of PDK1, which in turn phosphorylates AKT. We 
therefore immunoprecipitated endogenous PDK1 from HEK293T cells which were starved over night 
and then left starving or grown in medium complemented with insulin or with LY294003 - a PI3K 
inhibitor. Insulin was washed out and cells were harvested at different time points after washout. 
No difference in PDK1 ubiquitination levels was observed between stimulated and unstimulated 
cells (Figure 14c and d). This seems to indicate that PDK1 ubiquitination is not affected by activation 
of the PI3K/AKT pathway and conversely, that ubiquitination does not influence activation of 
downstream components. As suggested in Figure 9, we suspect that the mono-ubiquitinated lysine 
is located in the kinase domain of PDK1. To understand if ubiquitination of the kinase domain is 
important for PDK1 catalytic activity or catalytic activity is a prerequisite for ubiquitination, we 
created a catalytically inactive K110R mutant of PDK1. Lysine 110 is located in the catalytic center 
and crucial for wild type PDK1 kinase activity [26]. We overexpressed the K110R mutant and wild 
type PDK1 as control, in HEK293T cells and immunoprecipitated using a PDK1 specific antibody. Both 
the catalytically inactive and wild type PDK1 were mono-ubiquitinated (Figure 14e), which suggests 
this modifications is neither crucial nor dependent on catalytic activity. It has been suggested that 
phosphorylation of AKT by PDK1 is not strictly dependent on PIP3 binding via the PH domain of 
either protein [30], however binding PIP3 is thought to bring AKT and PDK1 into close enough 
contact to favor AKT phosphorylation and is therefore one of the regulators of PI3K/AKT pathway 
activation. We thus wanted to examine if PDK1 mono-ubiquitination played a role in PDK1 binding 
to PIP3. We overexpressed wild type PDK1 and the PDK1 K465E PH domain mutant which does not 
bind PIP3 [151] in HEK293T cells and affinity purified with PIP3-coated agarose beads. Non-coated 
agarose beads were used as control. As expected, the K465E mutant did not bind to PIP3 beads but 
wild type PDK1 was precipitated in both its ubiquitinated and non-ubiquitinated forms (Figure 14f). 
This suggests that mono-ubiquitination is not necessary for PDK1 binding to PIP3 as levels of 
ubiquitinated PDK1 are comparable in the whole cell lysate and the precipitate. Conversely it seems 
that PDK1 ubiquitination does not disrupt its ability to bind to PIP3. Overall our results suggest that 
mono-ubiquitination does not affect and is not essential for PDK1 localization, PIP3 binding or kinase 
activity and that ubiquitination levels do not change with PI3K/AKT pathway activation.  
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Figure 14 – Functional characterization of PDK1 mono-ubiquitination. 
a. Immunofluorescence visualized by confocal laser microscopy. HEK293T cells transfected with PDK1-V5, PDK1-V5-
Ubiquitination fusion, or GFP. Cells are stained with DAPI and with V5 antibody coupled to alexa fluor secondary antibody. 
b. Western blot with V5 (PDK1), Histone 1 (H1), HSP90 and actin (loading control) signal from cytoplasm, membrane, 
nuclear fractions in HEK293T cells. PDK1 was immunoprecipitated with V5 antibody. c. Western blot for endogenous 
immunoprecipitated PDK1, activated AKT (pAKT) and PCNA as loading control in unstimulated HEK293T or HEK293T 
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stimulated with insulin, with or without LY294003 PI3K inhibitor for 8h. d. Time course. Western blot for endogenous 
immunoprecipitated PDK1, AKT, activated AKT (pAKT) and PCNA as loading control in HEK293T stimulated with insulin. 
Insulin was washed out and cells were harvested after the times indicated. e. Western blot. IP in HEK293T cells ectopically 
expressing wt or K110R (catalytically inactive) PDK1. f. Western blot showing signal from AP using PIP3 coated beads, in 
HEK293T cells transfected with wild type PDK1 or PDK1 K465E (PIP3 binding deficient) mutant.   
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3 Discussion 
3.1 Mapping the lysine residue 
  
 We were able to show for the first time that PDK1 is endogenously mono-ubiquitinated in 
HEK293T cells in vivo and were also able to detect this ubiquitination via western blot. Our results 
suggest that this is also the case in HEP1, HeLa, K562, U2OS and A2780 cells. Our MS data also 
supports this finding, since ubiquitin peptides were detected in affinity purified PDK1 fraction of 
HEK293TSH WCL. To perform further functional characterization identifying the ubiquitinated lysine 
residue is crucial because it will allow experiments in a more focused and targeted manner to 
elucidate the role of mono-ubiquitination of PDK1. Mutating 14 conserved lysines to arginines did 
not cause loss of PDK1 mono-ubiquitination, indicating that none of these are likely to be used for 
mono-ubiquitin conjugation endogenously in HEK293 cells. Efforts to map the post translational 
modification site by truncating PDK1 did not yield a conclusive result due to the fact that most of the 
truncations were not stably expressed by the transfected cells. The lack of detectable middle-sized 
truncations could be due to the fact that most of our truncations form peptides that are labeled as 
misfolded proteins and degraded (Figure 7b). This hypothesis is supported by the fact that we can 
detect long truncations such as C-terminal #1, #2 and N-terminal #3, whereas smaller truncations 
such as #4, #5, #6 are lost to degradation. Lager truncations which lack only a few lysines may 
resemble full length PDK1 in their secondary structure close enough to pass as well folded proteins 
in the cell, and thus escape degradation, whilst shorter truncation may be too aberrant to do so. 
However, the fact that the smallest truncation #7 appears to be well expressed, and what's more, 
ubiquitinated, challenges the above explanation. This raises two questions: first, why is #7 stably 
expressed when larger truncations, which should have a less aberrant secondary structure are not? 
A possible answer to this is the fact that #7 has lost most of its kinase domain, and consists 
essentially only of a PH domain with a few amino acids reaching into the kinase domain. This may 
allow #7 to fold in such a way as to leave the peptide catalytically inactive but unscathed by quality 
control mechanisms. Larger truncations on the other hand, while also containing an intact PH 
domain, retain much larger portions of their kinase domain sequence. It may form folding 
intermediates which are recognized by quality control mechanisms such as chaperones and marked 
for ER-associated degradation (ERAD). However, the fact that we failed to see expression of the PH 
domain alone, argues against the idea of domain integrity being the crucial factor for overall peptide 
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stability. Secondly, the above raises the question if we can use this information to narrow down the 
ubiquitinated lysine. We were able to stably overexpress the kinase domain alone in HEK293T and 
found it to be ubiquitinated. This supports the fact that mono-ubiquitin may be conjugated to the 
kinase domain in endogenous PDK1. We furthermore established that ubiquitination does not 
depend on and is not required for PDK1 kinase activity. We suggest that the kinase domain bears the 
modification in wild type PDK1, a claim that is also supported by statistical probability, considering 
that the kinase domain contains 27 lysines versus only 5 in the PH domain and 5 in intermediate 
regions. Assuming that #7 is indeed ubiquitinated, we have no good explanation as to why we fail to 
see ubiquitination in larger and stably expressed truncations like #3 as well. A possible solution to 
circumvent the problem of truncation mutant instability could be to create substitution mutants by 
starting with a PDK1 mutant lacking all lysines and sequentially mutating arginines back to lysines, 
instead of eliminating lysines by truncating them off, and monitoring for a return of the 
ubiquitination signal. Alternatively, one could create lysine to arginine mutants for all the 38 lysines 
individually and screen for ubiquitination loss, however this would not be cost and time effective. 
This approach has an additional caveat since it cannot discriminate between situations where 
conjugation of the mono-ubiquitin occurs interchangeably at two or more lysines. If PDK1 mono-
ubiquitination was to occur at two or more different lysines randomly or with certain preference, 
mutating either lysine residue alone would not allow us to see a loss of ubiquitination even if one of 
the canonical ubiquitin-accepting sites on PDK1 was mutated.  
 
3.2 MS/MS: potential and limitations 
 
 Alternative approaches for identifying the ubiquitin conjugated lysine residue by AP-MS 
(Figure 10) were performed and we were able to isolate ubiquitinated PDK1 from HEK293SH cells 
with high enough efficiency and with little enough contamination by other proteins to visualize it by 
silver staining. MS/MS detected a ubiquitin fingerprint predominantly in the excised bands where 
expected. However predicted m/z fingerprint scores for GG remnant conjugated PDK1 peptides 
were not detected, and thus no ubiquitinated lysine residue was identified. A reason for this could 
be low sequence coverage i.e. “the fraction of the amino acid sequence that is represented by 
peptides in the peptide mass map” [152]. While low sequence coverage may suffice to identify the 
overall presence of a given protein with reasonable certainty in a sample, identification of PTMs is 
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by definition dependent on nearly complete sequence coverage to have a good probability of 
detection. Only if the site of modification is included in the mass fingerprints obtained by MS/MS, 
can it be detected and mapped. Several factors can be responsible for low coverage, such as a wide 
range in concentrations in a mixture of proteins or varying ESI efficiency, resulting in different ion 
intensities despite comparable concentrations of analytes [153]. Indeed, the PDK1-Ubiquitin band is 
weaker by a factor of around 50 than non-ubiquitinated PDK1 and thus small amounts of 
contaminants can create noise that easily impacts MS detection efficiency of the PTM. Another 
reason for lack of detection could be the choice of our inclusion lists. Because of technical 
limitations, of 121 peptides predicted in silico only 35 and 34 could be used in inclusion lists 1 and 2 
respectively, based on priority of lysines located within PDK1 active domains. It can be speculated 
that a new run of the sample with alternative inclusion lists may shift the sequence coverage to 
include the modified lysine residue. While AP-MS is currently the most powerful tool for the 
identification of PTMs, it also suffers from some general caveats and limitations which we will 
discuss below.  First, it has been shown that proteins that are ubiquitinated can also simultaneously 
be conjugated to other ubiquitin like (Ubl) modifiers, which can leave GG remnants just like 
ubiquitin after tryptic digestion. Examples for this are HDM2 which is modified by SUMO, ubiquitin 
and NEDD8 [154]. Indeed NEDD8, Rub1 and ISG15 all leave GG remnants. Since the detection of 
ubiquitinated residues depends on mass-shift caused by these remnants, loss of modifier identity 
can be a problem. A solution to this problem is the use of tags for affinity purification on the 
modifier that is being studied. Strep-HA purification has allowed sufficient enrichment for 
ubiquitinated PDK1 but none of our approaches that made use of tagged ubiquitin have allowed 
isolation of a sample analyzable by MS. Although we can be reasonably confident that the modifying 
moiety is ubiquitin, certainty will be obtained by repeating the assay using a tagged form of 
ubiquitin for isolation. Another known issue is the use of Iodoacetamide (IA), an alkylating agent 
used in standard protein digestion protocols to block cysteine residues, forms adducts on peptides 
which look like GG remnants in MS and thus create false positives [155]. We therefore avoided use 
of IA in our approaches. Second it has been reported that tagged modifiers have altered conjugation 
specificity. A study showed that Flag-tagged SUMO for example was conjugated at lower levels to 
proteins [156]. This could be a reason why we were unable to isolate ubiquitinated PDK1 by using 
epitope tagged ubiquitin. A solution to this could be the use of several different tags, since it is less 
likely that all of them would negatively impact conjugation. A quantitative preliminary screen to 
determine which of such tagged forms of ubiquitin is most readily conjugated may prove 
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challenging. An ELISA assay detecting ubiquitin levels on immobilized PDK1 could provide 
quantitative information. Third, Ubl modified proteins can be less abundant than their non-modified 
counterparts and the turnover can be high, with rapid conjugation and deconjugation [157]. This is 
the case here, where ubiquitinated PDK1 levels are significantly lower than unmodified PDK1. This 
makes the window of possible isolation small and limits the maximum possible yield, which is critical 
for MS based analysis. In the case of poly-ubiquitination, this may be counteracted by the use of 
proteasome inhibitors such as MG132, chemically modified non-deconjugable Ubls in the lysis buffer 
[158-159] or co-transfection of ubiquitin mutants such as G76A which forms chains that cannot be 
proteolyzed and deconjugated by DUBs [160]. In our assays we have used the general protease 
inhibitor N-ethylmaleimide to reduce the chances of PDK1 de-ubiquitination. A positive hit on the 
DUB screen that would reveal the identity of a DUB for PDK1 could also positively impact our MS 
experiments. If a DUB was known, its knock-down could be combined with AP-MS approaches to 
shift the equilibrium towards an increase of the amount of ubiquitinated PDK1 available for affinity 
isolation. Finally, MS data analysis algorithms may also form a bottleneck in the identification of 
ubiquitin modified lysines. Long Ubl tails - which may still be present in our samples from other, 
aspecifically enriched proteins - can themselves produce fragments by CID and thus create complex 
overlapping fragmentation patters that cannot be analyzed by conventional search algorithms. 
 
3.3 Finding the DUB  
 
 Detecting PDK1 mono-ubiquitination by western blot and the availability of shRNA and 
siRNA libraries allowed us to mount a loss of function screen to identify a DUB for PDK1. Of all the 
DUBs screened, none have yielded an increase in the ubiquitinated fraction and thus we have not 
found any DUB that acts on PDK1. We can therefore only speculate on the reasons. First, a western 
blot based screen may not be sensitive enough to pick up changes in mono-ubiquitination. Although 
we have shown that protein-G tagged and ectopically expressed PDK1 is mono-ubiquitinated and 
can be detected via western blot, there is no guarantee that a DUB will act on it as it would on 
endogenous PDK1-ubiquitin conjugates. It could be that the protein G-tagged version of PDK1 is 
either not recognized by the DUB or that, despite DUB activity, an excess of ubiquitinated PDK1 from 
overexpression makes the increase of ubiquitinated PDK1 signal undetectable due to quenching. 
This latter possibility means that despite having succeeded in knocking down the responsible DUB 
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via RNAi, our assay would not have been sensitive enough (i.e. too noisy) to pick up the change. An 
alternative approach such as an enzyme linked immunoabsorbent assay (ELISA) could be used to 
obtain a more quantitative signal. The human genome is predicted to encode as many as 95 DUBs 
based on sequence comparison analysis [87] and the pSUPER and Dharmacon libraries contain 
oligonucleotides targeting 50 and 100 genes respectively. Thus, the second possible explanation for 
a lack of detection of a change in ubiquitin signal, may be that the DUB for PDK1 is not yet known, 
thus not contained within either library and therefore not identifiable with either of them. Here a 
solution is technically more challenging: one possibility to identify the unknown DUB would be by a 
proteomics approach. High-throughput tandem affinity purification and mass spectrometry analysis 
(TAP-MS) is being used to identify protein interactomes in human cells [149]. This approach could be 
applied to identify novel interactors of PDK1, which would then have to be characterized 
functionally for de-ubiquitinase activity in vitro, for instance by LanthaScreen [161]. This approach 
comes with the caveat that the DUB-substrate interaction may be transient, which could reduce the 
yield of co-precipitated DUB available for MS-detection. Chemically cross-linking with reagents such 
as such as di-N-hydryoxysuccinimide, that crosslinks proteins via lysines can be used to increase to 
stabilize transient complexes, but the unspecificity of these approaches may cause false positives 
[162]. Yet such an approach has been reported in combination with TAP [163]. The third possibility is 
that some of the knock downs in our library may not have effectively silenced their target for 
technical reasons. Verifying every single shRNA pool is difficult but it may be possible to bypass this, 
by performing a gain of function (GOF) screen in addition to a loss of function (LOF) screen as was 
done here, by using a DUB cDNA overexpression library and looking for a loss of PDK1 ubiquitination 
rather than for an increase. This would reduce the chance that hits that were missed in the LOF 
screen are missed a second time. The fourth explanation why we failed to pick up an increase in 
signal could be redundancy in DUB action. If more than one DUB were to act on PDK1, knocking 
down one would not suffice to allow a change in ubiquitination status to become visible, as the 
silenced protease's action would be compensated by the other. So far, substrate sharing has not 
been reported in the literature, however there are examples of functional redundancy – as opposed 
to substrate redundancy - such as CYLD and A20, two DUBs that both negatively influence the NFκB 
signaling pathway [95, 164-165]. Last, it could be hypothesized that no DUB was found because no 
DUB exists that acts on PDK1 in HEK293T cells, making the mono-ubiquitination irreversible. This 
scenario seems unlikely however, because ubiquitination is likely to be a dynamic process, as 
suggested by the smaller fraction of PDK1 that is found to be modified. If PDK1 was constantly being 
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ubiquitinated and this ubiquitination has a non-degradative role – as we assume it does due to its 
detection on western blot – the proportion of ubiquitinated PDK1 would be dominant in the cell 
lysate. However this is clearly not the case. We have performed experiments with TS20 cells 
expressing a temperature sensitive E1 mutant (data not shown) allowing shut down of the ubiquitin 
machinery at a non permissive temperature [166]. Shutting down ubiquitination while monitoring 
for a decrease in ubiquitination levels of PDK1 can serve as a control for the existence of an active 
DUB. However, due to low total PDK1 stability in this cell line, no conclusive result was obtainable. 
We cannot completely exclude at this point that no DUB exists for PDK1 but it seems reasonable to 
assume that it does exist.  
   
3.4 Function of PDK1 mono-ubiquitination 
 
Attempts to characterize PDK1 mono-ubiquitination did not reveal a particular functional 
role; however we were able to exclude several possibilities. Binding of PDK1 to PIP3 was not 
dependent on mono-ubiquitination and conversely, binding was not essential for ubiquitination. 
Second, we showed that PDK1 kinase activity is not required for its ubiquitination. Third, we have 
created an epitope tagged C-terminal PDK1-ubiquitin fusion which we transfected and visualized by 
confocal laser microscopy to test for differential localization between ubiquitinated and non-
ubiquitinated forms. This construct did not seem to preferentially localize to the membrane, the 
cytoplasm or the nucleus. It can be argued however that this linear fusion is too artificial and does 
therefore not accurately mimic mono-ubiquitinated PDK1. This also suggests that, should 
endogenous mono-ubiquitin affect PDK1 localization, then it is not dependent on the mere presence 
of a ubiquitin moiety but requires recognition by a ubiquitin binding domain (UBD) that specifically 
recognizes the mono-ubiquitin epitope conjugated to a particular lysine. Alternatively, the fact that 
we did not observe a difference in localization of the PDK1-Ub fusion could be due to the fact that 
its effect on localization is too faint to be observed in confocal laser microscopy. A possible solution 
here could come from identifying the E3-ligase or E2/E3 complex responsible for mono-
ubiquitination of PDK1. Overexpressing the E3 ligase may be an alternative approach to enrich for 
ubiquitinated PDK1 and possibly observe differential localization. Fractionation of HEK293T cell 
lysate in membrane, nuclear and cytoplasmic fractions showed that PDK1 was ubiquitinated in all 
these cellular compartments thus further underlining that ubiquitination does not seem to play a 
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role in PDK1 localization. Fractionation with higher resolution, such as endosomal isolation, may yet 
reveal a differential repartition. Pathway activation by PDK1 was measured by the levels of 
phosphorylated AKT, but PDK1 ubiquitination levels remained constant. We therefore concluded 
that mono-ubiquitination does not correlate with pathway activity as measured by AKT 
phosphorylation levels. However, we can speculate that PDK1 may activate other of its downstream 
targets in a ubiquitin dependent manner. In such a scenario PDK1 mono-ubiquitination could serve 
to fine tune its activity towards substrates other than AKT. The fact that only a small fraction of 
PDK1 seems to be ubiquitinated could support this hypothesis. Activation levels of SGK, S6K, RSK 
and PKC were not measured in this work. A possibility to assay if mono-ubiquitination is involved in 
steering PDK1 activity towards different targets could be achieved by co-precipitating known 
substrates with PDK1 and monitoring mono-ubiquitination state of PDK1 in these complexes.  
 
3.5 Open questions and outlook 
 
Another important issue is how to proceed once the mono-ubiquitinated lysine residue is 
identified. Knowing the modification site is crucial to understand its role. For instance it will allow 
the creation of non-ubiquitinatable point mutants. Monitoring the activation status of downstream 
PDK1 substrates in cells overexpressing this mutant, may reveal a differential activation pattern of 
substrates, indicating that under normal conditions mono-ubiquitin is involved in regulation of a 
particular PDK1 substrate. Basal levels of endogenously ubiquitinated PDK1 will remain in 
transfected cells, which will be problematic if indeed mono-ubiquitination is a subtle differential 
activator that steers a subset of PDK1 molecules towards different substrates. This is difficult to 
prevent, without knowledge of the ubiquitin ligase. While overexpressing a non-modifiable mutant 
is easily feasible, but only of limited use, making a constitutively ubiquitinated PDK1 version is more 
challenging but may prove an informative tool. A possible way to address this problem is by 
identifying the E3 ligase responsible for PDK1 mono-ubiquitination and overexpressing it. This 
should allow to shift the equilibrium towards ubiquitination and bolster the levels of modified PDK1. 
Subsequently this can prove more representative by keeping the ubiquitin epitope endogenous 
instead of fusing it artificially to the protein. Constitutively highly ubiquitinated PDK1 might also 
prove valuable to study downstream activation, as it may allow us to identify which of PDK1’s 
substrates are dependent on mono-ubiquitin. This mutant may also be used in combination with the 
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above discussed point mutant. The E3 ligase specific for PDK1 can in theory be identified by affinity 
purification of PDK1 with its interactors from cell lysate in non-denaturing conditions, coupled with 
shotgun mass-spectrometry [167]. We have however not used this approach so far. Our MS/MS 
(orbitrap) setup described previously, does not identify peptides which are not on the inclusion list. 
Shotgun mass spectrometry uses scanning analyzers to generate great amounts of spectra from 
complex mixtures and is therefore suited for interactome studies, with the potential of identifying 
interactors. Ultimately, the search for PDK1 mono-ubiquitination aims at gaining better functional 
understanding of this kinase with hopes to offer a targeting strategy for this important kinase in 
cancers with activated PI3K/AKT. How likely is it, that given the identification of the ubiquitination 
site and the functional understanding of the modification, PDK1 will be a drug target in cancer? 
Several factors speak for the attractiveness of PDK1 as a target: it is constitutively active and 
essential for AKT function and inhibiting PDK1 is a way to reduce AKT activity indirectly, thus 
potentially being less favorable to development of resistance in the tumor. This raises the question 
of putative and in vivo effectiveness. It is not clear how distant a targeted molecule (node) of the 
same pathway can be from the actually mutated onco-protein to still be effective in inhibiting it. For 
instance, mTORC which is a target of AKT also exerts negative feedback on AKT. Thus, treating with 
mTORC inhibitors in tumors with activated AKT (e.g. with rapamycin and analogues) can worsen the 
situation. While over active AKT may favor transformation and proliferation, in some cases inhibiting 
mTORC will remove what little remaining negative control is left on AKT and can even further 
stimulate tumor growth [168]. This is one of the reasons why double inhibitors of mTORC and other 
PI3K pathway components are more promising than single components targeting the mTORC hub. 
Furthermore the cross-talk landscape amongst PI3K and other pathways like β-catenin [169] in 
tumors is starting to be filled in. It seems that PDK1 is essential enough for activation of AKT and its 
other substrates to be a solid target, especially in the context of drug combination treatments 
affecting more than one pathway. 
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4 Conclusions  
 
 In this work we have described for the first time that PDK1 is mono-ubiquitinated in vivo, 
and that this modification occurs in the kinase domain. Furthermore we have established that PDK1 
kinase activity is not required for its ubiquitination. We also present evidence that ubiquitination of 
PDK1 is not affected by insulin stimulus, by PIP3 binding and that ubiquitination does not affect 
PDK1's ability to bind to PIP3.  
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5 Materials and Methods 
 
Chemicals: Ampicillin (Roth); Big Dye for sequencing kit (AppliedBiosystems); D+Biotin 98% (Alfa 
Aesar); DAPI (Sigma-Aldrich); Di-ubiquitin (Boston Biochem); DMEM medium (Invitrogen GIBCO®); 
Fetal calf serum (FCS) (Invitrogen GIBCO®); HA beads (Sigma-Aldrich); LB agar (Roth); LY294003 
(Sigma-Aldrich); Lysogeny broth (LB) medium (Roth); Ni beads (Sigma-Aldrich); Nucleotides for PCR 
(Fermentas); Opti-MEM medium (Invitrogen GIBCO®); Phosphate buffered saline (PBS) (Sigma-
Aldrich); PIP3 beads (Echelon Biosciences); Polybrene (Sigma-Aldrich); Protein G beads (Pierce); 
Proteinase K (Sigma-Aldrich); Puromycin (Sigma-Aldrich);Restriction enzymes (New England Biolabs); 
RPMI 1640 medium (Invitrogen GIBCO®); Strep-tactin sepharose 50% suspension (IBA); Tergitol-
NP40 (Sigma-Aldrich); triton-x100 (Sigma-Aldrich); Trypsin from (Invitrogen GIBCO®); V5 beads 
(Sigma-Aldrich); VECTASHIELD (Vector Labs). Oligonucleotides were designed by us and and 
synthesized by Sigma-Aldrich (Germany). Antibodies: AKT (Cell Signaling); Alexa Fluor 488 secondary 
(invitrogen); IgG2a (Abcam); pAKT (Cell Signaling); PDK1 (Cell Signaling); Ubiquitin (P4D1) (Cell 
Signaling). 
 
10x Hepes Buffered Saline (HBS): 1.4 M NaCl, 250 mM HEPES, 7.5 mM Na2HP04, pH7.5, filter 
sterilized, stored at -20°C. 
SDS reducing sample buffer: 320 mM Tris-HCI pH 6.8, 40% (v/v) Glycerol, 0.008g bromphenol blue, 
8% SDS (stock is 20%), 20 % (v/v) beta-mercapto-ethanol  
RIPA cell lysis buffer: 25 mM Tris-HCl pH 7.6, 150 mM NaCl, 1 % NP40 or Tergitol, 0.5% Triton X100,  
0.1 % SDS 
Immunofluorescence blocking buffer: for 12.5ml = 1.25ml 10xPBS, 0.63ml Serum from the same 
species as the secondary Ab. While stiring add 375µl Triton X-100. Ad 12.5ml dH20 
Immunofluorescence Antibody dilution buffer: for 40ml = 4ml 10XPBS + 36ml dH2O. 0.4g BSA, 
while stiring add 120µl Triton X-100 
Agarose gel electrophoresis: Dissolve agarose in TAE (1 g/100ml). Boil mixture in microwave until 
the agarose is fully dissolved. Add Ethidium bromide 10 µl/100ml.  
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5.1 Mass Spectrometry, an emerging tool in ubiquitin studies 
 
 The ability to use affinity purification with mass spectrometry (AP-MS), to purify protein 
complexes under near physiological conditions and obtain amino acid sequence information for 
refined database search, has made AP-MS a method of choice in protein interactome studies [170]. 
It is also emerging as a tool to identify post translational modification sites on proteins conjugated 
to ubiquitin and ubiquitin-like modifiers (Ubl). For instance, MS has been employed successfully to 
identify the poly-ubiquitinated lysine residue on EGFR [171] and mono-ubiquitinated lysine on Sts2 
[77]. As discussed in the results section, we have used single epitope affinity purification and 
tandem affinity purification (TAP) to isolate ubiquitinated PDK1 from cells transfected, retrovirally 
transduced or Flip-recombined with vectors over-expressing epitope tagged PDK1 and/or ubiquitin. 
Expression and successful affinity purification of epitope tagged PDK1-ubiquitin conjugates was 
verified via western blot. PAGE separation and protein silver staining of isolated protein allows the 
visualization and excision of bands that run at the predicted height of modified PDK1. In order to be 
analyzed, isolated proteins and protein complexes are digested, for example with trypsin, which 
cleaves C-terminally of lysines or arginines unless they are followed by a proline. Tryptic digestion 
leads to smaller peptides, with a double glycine (GG) remnant from digested ubiquitin, covalently 
bound to the post-translationally modified lysine from the original protein [157]. The fragment 
peptides are sequence specific and in sum create a peptide mass fingerprint of the digested protein, 
which allows digest database matchmaking and identification of the protein [172]. Trypsin digestion 
is not 100% efficient and some lysines may be skipped, leading to so called missed cleavage sites 
(MCS), which may, in turn, give rise to peptides with more than one GG remnant in proteins 
conjugated to several Ubls or to heavier LRGG signatures instead of GG [66, 68, 97, 149, 173]. To 
take miscleavage into account, we used the MASCOT search algorithm allowing a less stringent two 
missed cleavage sites instead of one, as the bulk of the ubiquitin modifier may further reduce the 
tryptic digestion efficiency at the mono-ubiquitinated lysine, causing an additional MCS. We 
analyzed the peptides resulting from affinity purified and trypsin digested proteins by high 
performance liquid chromatography (LC) in line with ESI and a tandem MS approach - this is known 
as "hyphenated separation" - commonly annotated LC-ESI-MS/MS . A mass spectrometer consists of 
an ionizing source, one or more analyzer units and a detector.  Mixtures can be separated by LC 
prior to MS analysis which allows to separate peptides according to their retention time in the 
column, thus improving analysis sensitivity because different components of the analyzed mixture 
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enter the mass spectrometer sequentially as narrow focused bands [174]. ESI is a soft ionization 
method, leading to very little to no further fragmentation and is thus very frequently employed in 
analysis of biological samples, where the conservation of whole non-covalently bound protein 
complexes is essential. In ESI, the analyte is injected through a needle and dispersed into charged 
droplets by a high potential (2.5 - 4 kV) between the needle and a counter-electrode [174]. 
Ionization of tryptically digested proteins creates protonated and multiply charged peptides of 
different size and mass. Tandem mass spectrometry (MS/MS) is a process in which two mass 
spectrometry analyzers (such as ion traps) are coupled in line. In the first MS step, an m/z scan is 
used to isolate ions with an m/z corresponding to the intact peptide. In the second MS step, the 
peptide is first fragmented by collision induced dissociation (CID) - analyte ions are made to collide 
with inert gas particles such as He - and the resulting fragment ions are once again separated 
according to their m/z. In ion trap analyzers, molecular ions of all m/z ratios take up stable 
trajectories, and which can be made unstable and ejected sequentially from the trap [174]. In our 
setup this is done using a linear quadrupole ion trap (LTQ). Ejected ions of interest are determined 
by an inclusion list that we generated from in silico prediction of differentially charged PDK1 
fragment ions. The LTQ also acts as a collision chamber for CID [175]. Protonation is important for 
the way in which peptides fragment during CID. The most abundant fragment ions formed are bn 
and yn ions, where the charge is retained on the N-terminal and C-terminal fragment respectively, 
and where n indicates the number of amino acid residues from the respective terminus [174]. The 
specific mass (m) to charge (z) ratio - m/z - of CID fragment ions allows sequence determination of 
the original peptides. PTM signatures cause mass shifts, in the case of GG remnants +114.04 kDa, 
that affect the m/z signal. Using search algorithms like MASCOT that perform database 
matchmaking while taking into account these predicted shifts allow identification of the modified 
protein, as well as mapping of the site of PTM conjugation [157].  
  
Mass spectrometry setup. Our inclusion lists was generated using the freeware online tool Ubl 
Finder and encompassed double and triple charged PDK1 fragment ions unmodified and modified by 
the GG remnant. Additionally the lists include 2 ions of the ubiquitin peptide itself to allow detection 
of ubiquitin as positive control. 
 
MS analysis on a hybrid LTQ-OrbitrapXL. The analyses were performed in a data dependent 
acquisition mode using a top 6 collision induced dissociation (CID) method (up to 6 CID spectra were 
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acquired following each MS scan) and a dynamic exclusion for selected ions of 60s. No lock masses 
were employed. Maximal ion accumulation time allowed on the LTQ Orbitrap in CID mode was 150 
ms for MS ninth eLTQ and 1000ms in the C-trap. Automatic gain control was used to prevent 
overfilling of the ion traps and was set to 5000 ions in MSn mode for the LTQ and 106 ions for a full 
FTMS scan. Injection wave forms were activated for both LTQ and Orbitrap. Intact peptides were 
detected in the Orbitrap at 60000 resolution. 
 
MS Data Analysis. The acquired data were processed with Bioworksv3.3.1SP1 
(ThermoFisher,Waltham,MA,USA), dta files merged with an internally-developed program, and 
searched against the human SwissProt database v57.12 (including isoforms as obtained from 
varsplic.pl) with the search engine MASCOT (MatrixScience,London,UK). Submission to the search 
engines was via a Perlscript that performs an initial search with relatively broad mass tolerance so n 
both the precursor and fgmentions (10ppmand0.6Da,respectively). High-confidence peptide 
identifications are used to recalibrate all precursor and fragment ion masses prior to a second 
search with narrower mass tolerance (4ppmand0.3DaforCID). Two missed tryptic cleavage site was 
allowed. Carbamidomethyl was set as fixed modifications, and oxidized methionine, residual 
ubiquitin-specific GG- and LRGG-signatures were set as a variable modification. To validate the 
proteins, MASCOT output files were processed by internally developed parsers. For MASCOT, two 
unique peptides with an ion score > 18 (plus additional peptides from proteins fulfilling the criteria 
with an ion score > 10) are required. The validated proteins retrieved by the two algorithms are 
merged, any spectral conflicts discarded and grouped according to shared peptides. A false positive 
detection rate (FDR) of <0.25% and <0.1% (including the peptides exported with lower scores) was 
determined for proteins and peptides, respectively, by applying the same procedure against a 
reversed database. 
 
5.2 RNAi 
 
RNA interference (RNAi) is a powerful tool that can be used to perform loss of function screens, 
i.e. in Drosophila melanogaster [176] and Caenorhabditis elengans [177]. Gene silencing by RNAi is a 
two step process. When entering the cell, dsRNA is recognised in the cytoplasm by the Dicer 
nuclease and processed into smaller double stranded RNA fragments, known as small interfering 
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RNAs (siRNAs). These siRNAs are then bound by RNA-induced silencing complex (RISC), which uses 
the siRNAs as templates to degrade complementary mRNA in the cell, thus silencing gene expression 
in a sequence dependent manner. In mammalian cells, introduction of long dsRNAs leads to an 
interferon response that shuts down protein synthesis altoghether. Therefore, small hairpin RNAs 
(shRNAs) have been developed, that are processed into siRNAs without illiciting an interferon 
response. The advantage of using shRNAs over siRNAs is that although being slightly less efficient in 
knocking down the target gene, shRNAs are less transient and therefore knock down the target gene 
for longer. The synthesized shRNAs recruit the RISC complex, are degraded and used as templates 
for degradation of specific mRNAs in vivo. Berns et al. [178] and others have successfully used 
multiple shRNAs against the same target mRNA, thus leading to efficient knock down, whilst 
avoiding unspecific cytotoxicity mediated via the interferon pathway in transfected cells. With our 
current knowledge of human genome sequences, it has been possible to apply this approach to 
screens in human and other mammalian cells. For example, stable RNA interference has been used 
to identify new components of the p53 dependent senescence pathway [159], an inventory of 
essential cancer genes [160], genes involved in metastasis [161] and the deubiquitinating enzyme 
and tumor suppressor CYLD as a regulator of the NFκB pathway [96].  
 
5.3 shRNA DUB screen 
 
The screen was done by transfecting HEKTAP cells as follows. 2.5µl Silentfect in 100µl Optimem 
were mixed with 10nM DUB shRNA vector pool in 100µl Optimem and incubated at room 
temperature for 20’. Then added to 500.000 cells per well in a 6 well plate, and filled to a total 
volume of 1200µl DMEM.  
 
Dharmacon shRNA library: Dharmacon ON-TARGETplus™ SMARTpool® siRNA Library- Human 
deubiquitinating Enzymes (stock 1µM). 
Dharmacon siRNA DUB screen was done by transfecting HEKTAP cells as follows. 2.5µl Silentfect in 
100µl Optimem were mixed with 10nM DUB siRNA in 100µl Optimem and incubated at room 
temperature for 20’. Then added to 500.000 cells per well in a 6 well plate, and filled to a total 
volume of 1200µl DMEM.  
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Transformation of competent XL10Gold bacterial cells. 25µl competent cells are thawed on ice. 1-
2µl DNA are added, gently homogenized and and incubated on ice for 30min. Cells are heat shocked 
20sec at 42°C and cooled on ice 2min. Cells are then allowed to expand in LB without antibiotic for 
30min to 1h at 37°C. Transformed cells are plated on LB agarose plates over night and colonies are 
picked the following day. 
 
RT-PCR DUB library knock down verification. HEKTAP cells were transfected with shRNA/siRNA 
targeting DUBs, using Silentfect in 96 well format. After 72h RNA was isolated using RNeasy 
Minelute kit (Qiagen) according to the manufacturer's protocol. cDNA was synthesized and 
quantitative RT-PCR was performed. RNA isolated from siRNA samples was treated with TURBO™ 
DNAse (Applied Biosystems) prior to cDNA synthesis. From samples transfected with shRNA, 500ng 
RNA were incubated 10min at 70°C, then 2min on ice. For cDNA synthesis, we used 0.5 µg/µl 
Random Hexamere primer, Dithiothreitol (DTT) 0.1 M, 1mM dNTPs, 5X First-Strand Buffer (250 mM 
Tris-HCl pH 8.3, 375 mM KCl, 15 mM MgCl2) (Invitrogen), 200u MMLV reverse transcriptase 
(Invitrogen), 40u RNaseOUT™ Recombinant Ribonuclease Inhibitor (Invitrogen). Synthesis cycle: 
5min at 25°C, 45min at 37°C, 15min at 42°C, 20min at 70°C. Samples transfected with siRNA 
(Dharmacon) were treated with 5µl TURBO DNase 10x buffer + 1µl TURBO DNAse 2u/10µg RNA at 
37°C for 30min. After incubation 5µl inactivator is added and sample is incubated 5min at RT. 
Sample is centrifuged 1.5min at 13.000rpm and supernatant is collected. 500ng DNAse treated RNA 
is incubated with with 100µM random hexamere primer (fermentas) at 65°C for 5min. cDNA 
synthesis was done using RevertAid™ Reverse Transcriptase (fermentas) according to 
manufacturer’s protocol using 20u RiboLock™ RNase Inhibitor, 1mM dNTP final concentration, 200u 
RevertAid reverse transcriptase. Synthesis cycle: 10min at 25°C, 60min at 42°C, 10min at 70°C.  
 
RT-PCR was done using 5µl iTaq Sybr-Green (Biorad),  10 pmol/µl Primer mix, 1µl cDNA in 10µl 
total reaction volume. Cycle: 2min at 50°C, 10’ at 95°C, (15sec at 95, 1min at 60)x40.  
 
Primers for RT-PCR 
USP1 
Forward 5’TGTTACCATTTGTGGGACTG3’ 
Reverse 5’CCAGATTTAAAACGGGACA3’ 
USP3 
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Forward 5’CATACCACACCAGAGCCAA3’ 
Reverse5’GGCTGCCTTGCCATAAAGCA3’ 
USP32 
Forward5’TTCATCCGGGAAGTGCTTGG3’ 
Reverse5’TGCAGCCCTTTGGATGTTCC3’ 
USP7 
Forward5’ACGAGCCGGACGTTTCGA3’ 
Reverse5’GCGCCACTGTGACAAGCATC3’ 
USP9x 
Forward5’TCAGGATGTGGGTCGTTACA3’ 
Reverse5’TGTCTGCCAAGCCTTTTCTT3’ 
 
5.4 Tissue culture 
 
293T cells were cultured at 37°C, 5% CO2, in DMEM + 0.5% v/v Gibco® PenStrep (10mg/ml Penicillin 
and Streptomycin in 0.85% Saline) + 10% v/v heat inactivated FCS (heat inactivation: 30min at 56°C). 
For K562 cells, RPMI was used instead of DMEM. 
HEK 293T cells. Are human embryonic kidney cells transformed with adenovirus 5 DNA and thus 
rendered oncogenic [179]. 293T cells are derived from 293 cells by insertion and constitutive 
experession of the SV40 T-antigen, rendering them immortal. 293T cells are characterised by high 
transfectability.  
 
HEK293SH cell line was created using Flip-In recombination. Flp-In™ T-REx™ 293 Cells (invitrogen) 
are plated in one well of a 6-well plate (4 ml media/well). Transfect 200ng of LR 
(pcDNA5/FRT/TO/SH/GW-PDK1) construct+1g of pOG44 (Recombinase) vector using SilentFect. 
After transfection cells are split to 10cm dish. Selection: add 10 mL of DMEM to cells (Blasticidin HCl 
(38µg/mL); Hygromycin B (260µg/mL)). Almost all cells should die in a week. Maintenance: change 
media every 3 days (Blasticidin HCl (15µg/mL); Hygromycin B (100µg/mL)). Single colonies are 
confluent enough after 2-3 weeks. Trypsinize the plate, mix well to separate cells and plate the pool 
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onto another 10cm dish. Keep in selecting medium until next passage, then grow to make stock and 
to test expression. Induction of expression with 1g/mL Doxycycline for 24h.  
 
HEKTAP cell line was created by infecting HEK293T cells with a retroviral vector. Retrovirus was 
made as described in the methods, using pCDNA-Myc-PDK1. Infection was done in 10cm dishes. 
Replace medium with 5ml DMEM containing 10µg/ml polybrene. Virus is then added 1:30 v/v. 
Expression on the PDK1-myc by the cells was verified by western blot. 
 
Other cell lines used 
Cell line  Cell Type  Organ  Species 
Hacat  Keratinocyte  Skin  Human 
HeLa  Adenocarcinoma  Cervix  Human 
A2780  Carcinoma  Ovaries  Human 
HEP1 Hepatoma  Liver  Human 
A549  Alveolar basal epithelial carcinoma  Lung  Human 
K562  AML  Blood  Human 
U2OS  Osteocarcinoma  Bone  Human 
MEF Embryonic Fibroblast  Mouse 
 
Lipofection. Biorad® SilentFect™ lipid reagent was used to transfect cells with plasmid DNA. Cells are 
plated to 80% confluency. Medium on cells was replaced ca. 20-60min before transfection. 0.2µg, 
1.2µg, 3.2µg DNA are transfected respectively for 96well plates, 6well plates, 10cm tissue culture 
dishes. Per well, 250µl Gibco® Optimem was mixed separately with 4µl Silentfect, 1.2µg DNA (200ng 
GFP DNA). Both were then mixed and incubated at room temperature for 20min, and then added to 
the cells and the plate was incubated for 48h. 
 
Transfection with Calcium Chloride. Cells are plated to 80% confluency. Twenty minutes before 
transfection medium is replaced with fresh medium. For 10cm dish, 20 ug DNA, are mixed with 950 
µl 1x HBS and 50 µl 2.5 M CaCI2 are added under vortexing. Transfection mixture is added to the 
cells. For 6-well plate 3.2 ug DNA, 158 µl 1x HBS and 8.3 µl 2.5 M CaCI2 are used. One day after 
transfection medium is replaced. 
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Retrovirus production: HEK293T producer cells are CaCl2 transfected in 10cm plate format with 
0.92µg VSV-G, 7.08 µg pPol, 0.8µg CMV-GFP as transfection control and 1µg vector of interest 
containing a Puromycin resistance marker. Cells are selected in medium containing 2µg/ml 
Puromycin for 3-5 days. 
 
5.1 Fractionaton  
 
HEK293T cells were transfected with 18µg V5-PDK1 and 2µg CMV-GFP. The next day, transfected 
cells were washed with PBS and collected in eppendorf tube and fractionated using Proteoextract kit 
(Calbiochem) Cat# 539791 according to manufacturer's protocol. PDK1 was immunoprecipitated 
from fractions using V5 antibody. 
5.2 PAGE and Western blotting 
 
Cells were lysed directly in the 96 well plate, by adding 25µl SDS denaturing buffer buffer (4x stock: 
320mM Tris-HCl pH 6.8, 40% v/v Glycerol, 0.008g bromphenol blue, 8% SDS, 20% v/v beta-mercapto 
Ethanol). 8µl lysate were run on PAGE (Invitrogen® NuPAGE Novex 4-12% Bis-Tris Gels, 1.0 mm) at 
150V for approximately 2hours. Blotting was done at 400mA for 1h on polyvinylidenfluoride (PVDF) 
membranes. Membranes were blocked with Applied Biosystems® 2% (w/v) iBlock™ in PBS with 1% 
Tween for 30min and incubated with antibody for 4h at room temperature. Washing of the 
membrane was done with PBS + 1% Tween.  
 
5.3 Affinity Purification 
 
Immunoprecipitation. Lysis was done in 1ml RIPA buffer. Lysate was sonicated 2x6sec on ice, cell 
debris were pelleted and discarded by spinning at 14.000rpm for 10min at 4°C. Precipitation was 
done in pre-cleared lysate (with 10µl Protein A coupled agarose) with 20µl Protein A coupled 
agarose and 5µl antibody for 4h at 10°C. A fraction of the lysate was kept as whole cell lisate control. 
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Elution was done by boiling the beads for 3min at 95°C in 4x SDS denaturing buffer buffer (described 
above) and eluate was loaded on PAGE.  
 
Ni/His affinity purification. Lysis was done in 1ml RIPA buffer. Lysate was sonicated 2x6sec on ice, 
cell debris were pelleted and discarded by spinning at 14.000rpm for 10min at 4°C. Precipitation was 
done with 30µl Nickel coupled agarose for 4h at 10°C. A fraction of the lysate was kept as whole cell 
lisate control. Elution was done by boiling the beads for 3min at 95°C in 4x SDS denaturing buffer 
buffer (described above) and eluate was loaded on PAGE. 
 
Strepavidin/Strep-tactin purification. Lysis was done in 1ml RIPA buffer. Lysate was sonicated 
2x6sec on ice, cell debris were pelleted and discarded by spinning at 14.000rpm for 10min at 4°C. 
Precipitation was done with 400µl Strep-tactin sepharose packed column, washed 2x with lysis 
buffer. Elution was done using a 2.5mM  D+Biotin solution in lysis buffer. Strep-tactin is a 
streptavidin derivative engineered to bind the 8 amino acid peptide Trp-Ser-His-Pro-Gln-Phe-Glu-Lys 
(StrepII tag) via its biotin binding pocket [180]. StrepIII tag is sequential arrangement of StrepII tags 
with a poly-Gly and poly-Ser linker [181]. 
5.4 Sequencing 
 
BigDye® sequencing was done using 250ng Plasmid, 1µl 5x BigDye buffer provided by the 
manufacturer, 1µl BigDye 3.1® di-deoxynucleotide mix, 1µl Primer (10mM) in 10µl ddH2O total 
volume. PCR Program: 96°C 1’, 96°C 10”, (50°C 5” x26), 60°C 4’. BigDye purification was done using a 
250µl G50 sephadex bead (5% in H2O) column. BigDye reaction sample was mixed with 10µl 
formamide on a 96-well PCR plate. And boiled 2" at 98°C to denature strands prior to sanger 
sequencing. 
 
5.5 Gateway cloning 
 
Expression vectors used for retroviral transfection (PDK1-TEV-Myc-ProtG) and Flip recombination 
(PDK1-HA-Strep) were created by Gateway cloning. This site-specific two-step recombination 
method consists of inserting attB flanked DNA of interest (PCR product) into an entry clone (EC) 
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vector (BP reaction), which can then be transferred to a destination vector (DV) using recombinases 
specific for att recombination sites (LR reaction). attB-PDK1-attB was PCR amplified from pcDNA6-
PDK1-V5-His using the following primers. Sense primer: 
5'GGGGACAAGTTTGTACAAAAAAGCAGGCTCCGCCAGGACCACCAGCCAG3' Antisense primer: 
5'GGGGACCACTTTGTACAAGAAAGCTGGGTTCACTGCACAGCGGCGTC3'. BP Reaction: The EC was 
created by recombining the PCR product with pDONR backbone vector. 1µg pDONR, 3µg PCR DNA 
product, 2µl BP clonase and 4µl ddH20 were mixed and incubated for 1h at room temperature. To 
stop the reaction, 1µl Proteinase K was added and samples were incubated 10’ at room 
temperature. Ligation product was then transformed into XL10Gold competent bacteria as 
described in the methods. Transformed bugs were plated in agarose plates with kanamycin, colonies 
were picked the next day, grown up in liquid LB medium with kanamycin 30µg/ml. Plasmid DNA 
preparation was carried out according to protocol, and insert was sequenced by sanger sequencing. 
LR reaction: 3µg EC, 1µg destination vector, 2µl LR clonase and 4µl ddH20 were mixed and 
incubated 1h at room temperature. To stop the reaction, 1µl Proteinase K was added and samples 
were incubated 10’ at room temperature. 
 
PDK1 DNA sequence (H.sapiens): 
ATGGCCAGGACCACCAGCCAGCTGTATGACGCCGTGCCCATCCAGTCCAGCGTGGTGTTATGTTCCTGCCCAT
CCCCATCAATGGTGAGGACCCAGACTGAGTCCAGCACGCCCCCTGGCATTCCTGGTGGCAGCAGGCAGGGCC
CCGCCATGGACGGCACTGCAGCCGAGCCTCGGCCCGGCGCCGGCTCCCTGCAGCATGCCCAGCCTCCGCCGC
AGCCTCGGAAGAAGCGGCCTGAGGACTTCAAGTTTGGGAAAATCCTTGGGGAAGGCTCTTTTTCCACGGTTG
TCCTGGCTCGAGAACTGGCAACCTCCAGAGAATATGCGATTAAAATTCTGGAGAAGCGACATATCATAAAAG
AGAACAAGGTCCCCTATGTAACCAGAGAGCGGGATGTCATGTCGCGCCTGGATCACCCCTTCTTTGTTAAGCT
TTACTTCACATTTCAGGACGACGAGAAGCTGTATTTCGGCCTTAGTTATGCCAAAAATGGAGAACTACTTAAAT
ATATTCGCAAAATCGGTTCATTCGATGAGACCTGTACCCGATTTTACACGGCTGAGATTGTGTCTGCTTTAGAG
TACTTGCACGGCAAGGGCATCATTCACAGGGACCTTAAACCGGAAAACATTTTGTTAAATGAAGATATGCACA
TCCAGATCACAGATTTTGGAACAGCAAAAGTCTTATCCCCAGAGAGCAAACAAGCCAGGGCCAACTCATTCGT
GGGAACAGCGCAGTACGTTTCTCCAGAGCTGCTCACGGAGAAGTCCGCCTGTAAGAGTTCAGACCTTTGGGC
TCTTGGATGCATAATATACCAGCTTGTGGCAGGACTCCCACCATTCCGAGCTGGAAACGAGTATCTTATATTTC
AGAAGATCATTAAGTTGGAATATGACTTTCCAGAAAAATTCTTCCCTAAGGCAAGAGACCTCGTGGAGAAACT
TTTGGTTTTAGATGCCACAAAGCGGTTAGGCTGTGAGGAAATGGAAGGATACGGACCTCTTAAAGCACACCC
GTTCTTCGAGTCCGTCACGTGGGAGAACCTGCACCAGCAGACGCCTCCGAAGCTCACCGCTTACCTGCCGGCT
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ATGTCGGAAGACGACGAGGACTGCTATGGCAATTATGACAATCTCCTGAGCCAGTTTGGCTGCATGCAGGTG
TCTTCGTCCTCCTCCTCACACTCCCTGTCAGCCTCCGACACGGGCCTGCCCCAGAGGTCAGGCAGCAACATAGA
GCAGTACATTCACGATCTGGACTCGAACTCCTTTGAACTGGACTTACAGTTTTCCGAAGATGAGAAGAGGTTG
TTGTTGGAGAAGCAGGCTGGCGGAAACCCTTGGCACCAGTTTGTAGAAAATAATTTAATACTAAAGATGGGC
CCAGTGGATAAGCGGAAGGGTTTATTTGCAAGACGACGACAGCTGTTGCTCACAGAAGGACCACATTTATAT
TATGTGGATCCTGTCAACAAAGTTCTGAAAGGTGAAATTCCTTGGTCACAAGAACTTCGACCAGAGGCCAAGA
ATTTTAAAACTTTCTTTGTCCACACGCCTAACAGGACGTATTATCTGATGGACCCCAGCGGGAACGCACACAA
GTGGTGCAGGAAGATCCAGGAGGTTTGGAGGCAGCGATACCAGAGCCACCCGGACGCCGCTGTGCAGTGA 
 
PDK1 amino acid sequence (H.sapiens): 
MARTTSQLYDAVPIQSSVVLCSCPSPSMVRTQTESSTPPGIPGGSRQGPAMDGTAAEPRPGAGSLQHAQPPPQP
RKKRPEDFKFGKILGEGSFSTVVLARELATSREYAIKILEKRHIIKENKVPYVTRERDVMSRLDHPFFVKLYFTFQDDEK
LYFGLSYAKNGELLKYIRKIGSFDETCTRFYTAEIVSALEYLHGKGIIHRDLKPENILLNEDMHIQITDFGTAKVLSPESK
QARANSFVGTAQYVSPELLTEKSACKSSDLWALGCIIYQLVAGLPPFRAGNEYLIFQKIIKLEYDFPEKFFPKARDLVE
KLLVLDATKRLGCEEMEGYGPLKAHPFFESVTWENLHQQTPPKLTAYLPAMSEDDEDCYGNYDNLLSQFGCMQV
SSSSSSHSLSASDTGLPQRSGSNIEQYIHDLDSNSFELDLQFSEDEKRLLLEKQAGGNPWHQFVENNLILKMGPVDK
RKGLFARRRQLLLTEGPHLYYVDPVNKVLKGEIPWSQELRPEAKNFKTFFVHTPNRTYYLMDPSGNAHKWCRKIQE
VWRQRYQSHPDAAVQ 
 
Ubiquitin B sequence (H.sapiens): 
ATGGGCGCACCCTGTCTGACTACAACATCCAGAAAGAGTCCACCCTGCACCTGGTGCTCCGTCTCAGAGGTGG
G 
 
GFP sequence:  
TTGGGGTTGCGCCTTTTCCAAGGCAGCCCTGGGTTTGCGCAGGGACGCGGCTGCTCTGGGCGTGGTTCCGGG
AAACGCAGCGGCGCCGACCCTGGGTCTCGCACATTCTTCACGTCCGTTCGCAGCGTCACCCGGATCTTCGCCG
CTACCCTTGTGGGCCCCCCGGCGACGC 
 
PDK1 kinase domain (KD) and PDK1 PH domain (PH) expression vectors were created by PCR 
amplifying the coding sequence for the respective domains and cloning them into pcDNA6 
(Invitrogen) using EcoRI and XbaI. For KD, forward primer 
5'GATCGAATTCCCACCATGGCCAGGACCACCAGC3', reverse primer  
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5'GATCTCTAGACGGGTGAGCTTCGGAGGCGTC3'.  
For PH, forward primer 5'GATCGAATTCATGCAGCAACATAGAGCAGTA3', reverse primer  
5'GATCTCTAGACGCTGCACAGCGGCGTCCGG3'. 
 
Ubiquitin expression vector was made by PCR amplifying monomeric human ubiquitin B and cloning 
it into a pLKO2 (Invitrogen) backbone using restriction sites EcoRI and BstXI. Forward primer: 
5'TGGGCGCACCCTGTCTGACT3', reverse primer 5'CCACCTCTGAGACGGAGCACCA3'. This construct 
was sequence verified by sanger sequencing using CMV promotor specific primer 
5'CAAGCGGCCTCTGATAACCA3'. 
 
Flag-ubiquitin expression vector, was created by cloning human ubiquitin B into pcDNA3.1 
backbone containing a Flag sequence (pVLAG) using restriction sites BamHI and XbaI.  
 
HA-ubiquitin expression vector was ordered from Addgene (pRK5-HA-Ubiquitin-WT) 
His-ubiquitin expression vector was created by cloning human ubiquitin B into pcDNA3 backbone 
using restriction sites BamHI and XbaI. 
 
PDK1-V5-His expression vector was made by PCR amplifying PDK1 wild type sequence (forward 
primer 5' GAATTC GCCAGGACCACCAGCCAG 3‘, reverse primer 5'TCACTGCACAGCGGCGTCTCTAGA3' 
containing restriction sites) and cloning it into pcDNA6 eukaryotic expression vector backbone using 
the EcoRI and XbaI sites. 
PDK1-Ub fusion expression vector was created by PCR amplifying human ubiquitin B and cloning it 
5' of PDK1 in pcDNA6-PDK1-V5-His using KpnI/EcoRI 
 
PDK1-TEV-HA-Protein G TAP expression vector was made by gateway cloning. Entry clone was made 
by cloning PCR amplified human PDK1 wt sequence into pDONR (Invitrogen) by Gateway cloning BP 
recombinase. Transfer into expression vector pRVN was done with LR recombinase. Gateway cloning 
is described in the methods. Primers used for PCR:  
Sense primer 5‘ GGGG ACA AGT TTGTAC AAA AAA GCA GGC TCC 
GCCAGGACCACCAGCCAG 3‘, Antisense primer 5‘ GGGG AC CAC 
TTT GTA CAA GAA AGC TGG GT TCACTGCACAGCGGCGTC 3‘ . 
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Construct was verified by test digest using BsrGI restriction enzyme and agarose gel electrophoresis 
to check for insert size, and by Sanger sequencing. 
 
PDK1-HA-Strep TAP expression vector was created by gateway cloning. Entry clone was made by 
cloning PCR amplified human PDK1 wt sequence into pDONR (Invitrogen) by Gateway cloning BP 
recombinase. Transfer into expression clone pcDNA5/FRT/TO/SH/GW [149] was done with LR 
recombinase. Gateway cloning is described in the methods. Primers 
used for PCR:  
Sense primer 5‘ GGGG ACA AGT TTGTAC AAA AAA GCA GGC TCC 
GCCAGGACCACCAGCCAG 3‘, Antisense primer 5‘ GGGG AC CAC TTT GTA 
CAA GAA AGC TGG GT TCACTGCACAGCGGCGTC 3‘ . 
Construct was verified by test digest using BsrGI restriction enzyme and 
agarose gel electrophoresis to check for insert size, and by Sanger 
sequencing. 
5.6 PDK1 lysine mutants  
 
Mutants were created using the Quickchange II kit (Stratagene), according to manufactuerer's 
protocol and using the following primers. Conserved Lysines (Homo S., C. Elegans , Drosophila M.) 
were mutated to Arginine. 
  
1. K123R  
AAG -> AGG 
Forward 5'CGACATATCATAAAAGAGAACAGGGTCCCCTATGTAACCAG3' 
Reverse 5'CTGGTTACATAGGGGACCCTGTTCTCTTTTATGATATGTCG3' 
 2. K207R 
AAA -> AGA 
Forward 5'CATCATTCACAGGGACCTTAGACCGGAAAACATTTTGTTAAATG3' 
Reverse 5'CATTTAACAAAATGTTTTCCGGTCTAAGGTCCCTGTGAATGATG3' 
 3. K293/296R 
AAG -> AGG 
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AAG -> AGG 
Forward 5'GGAAACGAGTATCTTATATTTCAGAGGATCATTAGGTTGGAATATGACTTTCCAG3' 
Reverse 5'CTGGAAAGTCATATTCCAACCTAATGATCCTCTGAAATATAAGATACTCGTTTCC3' 
 4. K315R 
AAA -> AGA 
Forward 5'GAGACCTCGTGGAGAGACTTTTGGTTTTAGATGCC3' 
Reverse 5'GGCATCTAAAACCAAAAGTCTCTCCACGAGGTCTC3' 
 5. K435R 
AAG -> AGG 
Forward 5'GTTTTCCGAAGATGAGAGGAGGTTGTTGTTGGAGAAG3' 
Reverse 5'CTTCTCCAACAACAACCTCCTCTCATCTTCGGAAAAC3' 
 6. K441R 
AAG -> AGG 
Forward 5'GTTGTTGTTGGAGAGGCAGGCTGGCGGAAAC3' 
Reverse 5'GTTTCCGCCAGCCTGCCTCTCCAACAACAAC3' 
 7. K459R 
AAG -> AGG 
Forward 5'GAAAATAATTTAATACTAAGGATGGGCCCAGTGGATAAGCGG3' 
Reverse 5'CCGCTTATCCACTGGGCCCATCCTTAGTATTAAATTATTTTC3' 
 8. K465/467R 
AAG -> AGG 
AAG -> AGG 
Forward 5'GGGCCCAGTGGATAGGCGGAGGGGTTTATTTGCAAG3' 
Reverse 5'CTTGCAAATAAACCCCTCCGCCTATCCACTGGGCCC3' 
 9. K492/494R 
AAA -> AGA 
AAA -> AGA 
Forward 5'GTGGATCCTGTCAACAGAGTTCTGAGAGGTGAAATTCCTTGG3' 
Reverse 5'CCAAGGAATTTCACCTCTCAGAACTCTGTTGACAGGATCCAC3' 
 10. K509R 
AAG -> AGG 
Forward 5'GAACTTCGACCAGAGGCCAGGAATTTTAAAACTTTCTTTG3' 
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Reverse 5'CAAAGAAAGTTTTAAAATTCCTGGCCTCTGGTCGAAGTTC3' 
 
 
 
5.7 PDK1 Truncation mutants  
 
Truncations were made using the following primers and based on the PDK1 wild type sequence. C 
terminal truncations were cloned into pcDNA3.1 containing a Flag sequence (pVLAG) using BamHI 
and XbaI. N terminal truncations were cloned into pcDNA6-V5-His using KpnI and XbaI.  
C-terminal truncations forward primer (constant) 5'GATCGGATCCGCCAGGACCACCAGCCAG3'.  
C-terminal truncations reverse primers:  
5'GATCTCTAGACTAGTTGACAGGATCCACATAATATAAATG3' 
5'GATCTCTAGACTAATCCACTGGGCCCATCTTTAG3' 
N-terminal truncations reverse primer (constant) 5'GATCTCTAGACTCTGCACAGCGGCGTCCGG3'. 
N-terminal forward primers: 
5' GATCGGTACCCCACCATGATCCTTGGGGAAGGCTCTTTTTC3' 
5'GATCGGTACCCCACCATGGTCCCCTATGTAACCAGAG3' 
5'GATCGGTACCCCACCATGTATATTCGCAAAATCGGTTC3' 
5'GATCGGTACCCCACCATGTCTTATCCCCAGAGAGCAAAC3' 
5'GATCGGTACCCCACCATGATCATTAAGTTGGAATATG3' 
5'GATCGGTACCCCACCATGCTTTTGGTTTTAGATGCC 3' 
 
N-terminal PDK1 truncations 
(1) 1440bp 
GATCGGTACCCCACCATGATCCTTGGGGAAGGCTCTTTTTCCACGGTTGTCCTGGCTCGAGAACTGGCAACCT
CCAGAGAATATGCGATTAAAATTCTGGAGAAGCGACATATCATAAAAGAGAACAAGGTCCCCTATGTAACCA
GAGAGCGGGATGTCATGTCGCGCCTGGATCACCCCTTCTTTGTTAAGCTTTACTTCACATTTCAGGACGACGA
GAAGCTGTATTTCGGCCTTAGTTATGCCAAAAATGGAGAACTACTTAAATATATTCGCAAAATCGGTTCATTC
GATGAGACCTGTACCCGATTTTACACGGCTGAGATTGTGTCTGCTTTAGAGTACTTGCACGGCAAGGGCATCA
TTCACAGGGACCTTAAACCGGAAAACATTTTGTTAAATGAAGATATGCACATCCAGATCACAGATTTTGGAAC
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AGCAAAAGTCTTATCCCCAGAGAGCAAACAAGCCAGGGCCAACTCATTCGTGGGAACAGCGCAGTACGTTTC
TCCAGAGCTGCTCACGGAGAAGTCCGCCTGTAAGAGTTCAGACCTTTGGGCTCTTGGATGCATAATATACCAG
CTTGTGGCAGGACTCCCACCATTCCGAGCTGGAAACGAGTATCTTATATTTCAGAAGATCATTAAGTTGGAAT
ATGACTTTCCAGAAAAATTCTTCCCTAAGGCAAGAGACCTCGTGGAGAAACTTTTGGTTTTAGATGCCACAAA
GCGGTTAGGCTGTGAGGAAATGGAAGGATACGGACCTCTTAAAGCACACCCGTTCTTCGAGTCCGTCACGTG
GGAGAACCTGCACCAGCAGACGCCTCCGAAGCTCACCGCTTACCTGCCGGCTATGTCGGAAGACGACGAGGA
CTGCTATGGCAATTATGACAATCTCCTGAGCCAGTTTGGCTGCATGCAGGTGTCTTCGTCCTCCTCCTCACACT
CCCTGTCAGCCTCCGACACGGGCCTGCCCCAGAGGTCAGGCAGCAACATAGAGCAGTACATTCACGATCTGG
ACTCGAACTCCTTTGAACTGGACTTACAGTTTTCCGAAGATGAGAAGAGGTTGTTGTTGGAGAAGCAGGCTG
GCGGAAACCCTTGGCACCAGTTTGTAGAAAATAATTTAATACTAAAGATGGGCCCAGTGGATAAGCGGAAG
GGTTTATTTGCAAGACGACGACAGCTGTTGCTCACAGAAGGACCACATTTATATTATGTGGATCCTGTCAACA
AAGTTCTGAAAGGTGAAATTCCTTGGTCACAAGAACTTCGACCAGAGGCCAAGAATTTTAAAACTTTCTTTGT
CCACACGCCTAACAGGACGTATTATCTGATGGACCCCAGCGGGAACGCACACAAGTGGTGCAGGAAGATCCA
GGAGGTTTGGAGGCAGCGATACCAGAGCCACCCGGACGCCGCTGTGCAGAGTCTAGAGATC  
 
(2) 1329bp 
GATCGGTACCCCACCATGGTCCCCTATGTAACCAGAGAGCGGGATGTCATGTCGCGCCTGGATCACCCCTTCT
TTGTTAAGCTTTACTTCACATTTCAGGACGACGAGAAGCTGTATTTCGGCCTTAGTTATGCCAAAAATGGAGA
ACTACTTAAATATATTCGCAAAATCGGTTCATTCGATGAGACCTGTACCCGATTTTACACGGCTGAGATTGTGT
CTGCTTTAGAGTACTTGCACGGCAAGGGCATCATTCACAGGGACCTTAAACCGGAAAACATTTTGTTAAATGA
AGATATGCACATCCAGATCACAGATTTTGGAACAGCAAAAGTCTTATCCCCAGAGAGCAAACAAGCCAGGGC
CAACTCATTCGTGGGAACAGCGCAGTACGTTTCTCCAGAGCTGCTCACGGAGAAGTCCGCCTGTAAGAGTTC
AGACCTTTGGGCTCTTGGATGCATAATATACCAGCTTGTGGCAGGACTCCCACCATTCCGAGCTGGAAACGAG
TATCTTATATTTCAGAAGATCATTAAGTTGGAATATGACTTTCCAGAAAAATTCTTCCCTAAGGCAAGAGACCT
CGTGGAGAAACTTTTGGTTTTAGATGCCACAAAGCGGTTAGGCTGTGAGGAAATGGAAGGATACGGACCTCT
TAAAGCACACCCGTTCTTCGAGTCCGTCACGTGGGAGAACCTGCACCAGCAGACGCCTCCGAAGCTCACCGC
TTACCTGCCGGCTATGTCGGAAGACGACGAGGACTGCTATGGCAATTATGACAATCTCCTGAGCCAGTTTGGC
TGCATGCAGGTGTCTTCGTCCTCCTCCTCACACTCCCTGTCAGCCTCCGACACGGGCCTGCCCCAGAGGTCAG
GCAGCAACATAGAGCAGTACATTCACGATCTGGACTCGAACTCCTTTGAACTGGACTTACAGTTTTCCGAAGA
TGAGAAGAGGTTGTTGTTGGAGAAGCAGGCTGGCGGAAACCCTTGGCACCAGTTTGTAGAAAATAATTTAAT
ACTAAAGATGGGCCCAGTGGATAAGCGGAAGGGTTTATTTGCAAGACGACGACAGCTGTTGCTCACAGAAG
GACCACATTTATATTATGTGGATCCTGTCAACAAAGTTCTGAAAGGTGAAATTCCTTGGTCACAAGAACTTCG
 78 
 
ACCAGAGGCCAAGAATTTTAAAACTTTCTTTGTCCACACGCCTAACAGGACGTATTATCTGATGGACCCCAGC
GGGAACGCACACAAGTGGTGCAGGAAGATCCAGGAGGTTTGGAGGCAGCGATACCAGAGCCACCCGGACG
CCGCTGTGCAGAGTCTAGAGATC  
 
(3) 1191bp 
GATCGGTACCCCACCATGTATATTCGCAAAATCGGTTCATTCGATGAGACCTGTACCCGATTTTACACGGCTG
AGATTGTGTCTGCTTTAGAGTACTTGCACGGCAAGGGCATCATTCACAGGGACCTTAAACCGGAAAACATTTT
GTTAAATGAAGATATGCACATCCAGATCACAGATTTTGGAACAGCAAAAGTCTTATCCCCAGAGAGCAAACA
AGCCAGGGCCAACTCATTCGTGGGAACAGCGCAGTACGTTTCTCCAGAGCTGCTCACGGAGAAGTCCGCCTG
TAAGAGTTCAGACCTTTGGGCTCTTGGATGCATAATATACCAGCTTGTGGCAGGACTCCCACCATTCCGAGCT
GGAAACGAGTATCTTATATTTCAGAAGATCATTAAGTTGGAATATGACTTTCCAGAAAAATTCTTCCCTAAGG
CAAGAGACCTCGTGGAGAAACTTTTGGTTTTAGATGCCACAAAGCGGTTAGGCTGTGAGGAAATGGAAGGA
TACGGACCTCTTAAAGCACACCCGTTCTTCGAGTCCGTCACGTGGGAGAACCTGCACCAGCAGACGCCTCCGA
AGCTCACCGCTTACCTGCCGGCTATGTCGGAAGACGACGAGGACTGCTATGGCAATTATGACAATCTCCTGAG
CCAGTTTGGCTGCATGCAGGTGTCTTCGTCCTCCTCCTCACACTCCCTGTCAGCCTCCGACACGGGCCTGCCCC
AGAGGTCAGGCAGCAACATAGAGCAGTACATTCACGATCTGGACTCGAACTCCTTTGAACTGGACTTACAGTT
TTCCGAAGATGAGAAGAGGTTGTTGTTGGAGAAGCAGGCTGGCGGAAACCCTTGGCACCAGTTTGTAGAAA
ATAATTTAATACTAAAGATGGGCCCAGTGGATAAGCGGAAGGGTTTATTTGCAAGACGACGACAGCTGTTGC
TCACAGAAGGACCACATTTATATTATGTGGATCCTGTCAACAAAGTTCTGAAAGGTGAAATTCCTTGGTCACA
AGAACTTCGACCAGAGGCCAAGAATTTTAAAACTTTCTTTGTCCACACGCCTAACAGGACGTATTATCTGATG
GACCCCAGCGGGAACGCACACAAGTGGTGCAGGAAGATCCAGGAGGTTTGGAGGCAGCGATACCAGAGCC
ACCCGGACGCCGCTGTGCAGAGTCTAGAGATC  
 
(4) 1013bp 
GATCGGTACCCCACCATGTCTTATCCCCAGAGAGCAAACAAGCCAGGGCCAACTCATTCGTGGGAACAGCGC
AGTACGTTTCTCCAGAGCTGCTCACGGAGAAGTCCGCCTGTAAGAGTTCAGACCTTTGGGCTCTTGGATGCAT
AATATACCAGCTTGTGGCAGGACTCCCACCATTCCGAGCTGGAAACGAGTATCTTATATTTCAGAAGATCATT
AAGTTGGAATATGACTTTCCAGAAAAATTCTTCCCTAAGGCAAGAGACCTCGTGGAGAAACTTTTGGTTTTAG
ATGCCACAAAGCGGTTAGGCTGTGAGGAAATGGAAGGATACGGACCTCTTAAAGCACACCCGTTCTTCGAGT
CCGTCACGTGGGAGAACCTGCACCAGCAGACGCCTCCGAAGCTCACCGCTTACCTGCCGGCTATGTCGGAAG
ACGACGAGGACTGCTATGGCAATTATGACAATCTCCTGAGCCAGTTTGGCTGCATGCAGGTGTCTTCGTCCTC
CTCCTCACACTCCCTGTCAGCCTCCGACACGGGCCTGCCCCAGAGGTCAGGCAGCAACATAGAGCAGTACATT
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CACGATCTGGACTCGAACTCCTTTGAACTGGACTTACAGTTTTCCGAAGATGAGAAGAGGTTGTTGTTGGAGA
AGCAGGCTGGCGGAAACCCTTGGCACCAGTTTGTAGAAAATAATTTAATACTAAAGATGGGCCCAGTGGATA
AGCGGAAGGGTTTATTTGCAAGACGACGACAGCTGTTGCTCACAGAAGGACCACATTTATATTATGTGGATC
CTGTCAACAAAGTTCTGAAAGGTGAAATTCCTTGGTCACAAGAACTTCGACCAGAGGCCAAGAATTTTAAAA
CTTTCTTTGTCCACACGCCTAACAGGACGTATTATCTGATGGACCCCAGCGGGAACGCACACAAGTGGTGCAG
GAAGATCCAGGAGGTTTGGAGGCAGCGATACCAGAGCCACCCGGACGCCGCTGTGCAGAGTCTAGAGATC  
 
(5) 819bp 
GATCGGTACCCCACCATGATCATTAAGTTGGAATATGACTTTCCAGAAAAATTCTTCCCTAAGGCAAGAGACC
TCGTGGAGAAACTTTTGGTTTTAGATGCCACAAAGCGGTTAGGCTGTGAGGAAATGGAAGGATACGGACCTC
TTAAAGCACACCCGTTCTTCGAGTCCGTCACGTGGGAGAACCTGCACCAGCAGACGCCTCCGAAGCTCACCG
CTTACCTGCCGGCTATGTCGGAAGACGACGAGGACTGCTATGGCAATTATGACAATCTCCTGAGCCAGTTTGG
CTGCATGCAGGTGTCTTCGTCCTCCTCCTCACACTCCCTGTCAGCCTCCGACACGGGCCTGCCCCAGAGGTCAG
GCAGCAACATAGAGCAGTACATTCACGATCTGGACTCGAACTCCTTTGAACTGGACTTACAGTTTTCCGAAGA
TGAGAAGAGGTTGTTGTTGGAGAAGCAGGCTGGCGGAAACCCTTGGCACCAGTTTGTAGAAAATAATTTAAT
ACTAAAGATGGGCCCAGTGGATAAGCGGAAGGGTTTATTTGCAAGACGACGACAGCTGTTGCTCACAGAAG
GACCACATTTATATTATGTGGATCCTGTCAACAAAGTTCTGAAAGGTGAAATTCCTTGGTCACAAGAACTTCG
ACCAGAGGCCAAGAATTTTAAAACTTTCTTTGTCCACACGCCTAACAGGACGTATTATCTGATGGACCCCAGC
GGGAACGCACACAAGTGGTGCAGGAAGATCCAGGAGGTTTGGAGGCAGCGATACCAGAGCCACCCGGACG
CCGCTGTGCAGAGTCTAGAGATC  
 
(6) 753bp 
GATCGGTACCCCACCATGCTTTTGGTTTTAGATGCCACAAAGCGGTTAGGCTGTGAGGAAATGGAAGGATAC
GGACCTCTTAAAGCACACCCGTTCTTCGAGTCCGTCACGTGGGAGAACCTGCACCAGCAGACGCCTCCGAAG
CTCACCGCTTACCTGCCGGCTATGTCGGAAGACGACGAGGACTGCTATGGCAATTATGACAATCTCCTGAGCC
AGTTTGGCTGCATGCAGGTGTCTTCGTCCTCCTCCTCACACTCCCTGTCAGCCTCCGACACGGGCCTGCCCCAG
AGGTCAGGCAGCAACATAGAGCAGTACATTCACGATCTGGACTCGAACTCCTTTGAACTGGACTTACAGTTTT
CCGAAGATGAGAAGAGGTTGTTGTTGGAGAAGCAGGCTGGCGGAAACCCTTGGCACCAGTTTGTAGAAAAT
AATTTAATACTAAAGATGGGCCCAGTGGATAAGCGGAAGGGTTTATTTGCAAGACGACGACAGCTGTTGCTC
ACAGAAGGACCACATTTATATTATGTGGATCCTGTCAACAAAGTTCTGAAAGGTGAAATTCCTTGGTCACAAG
AACTTCGACCAGAGGCCAAGAATTTTAAAACTTTCTTTGTCCACACGCCTAACAGGACGTATTATCTGATGGA
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CCCCAGCGGGAACGCACACAAGTGGTGCAGGAAGATCCAGGAGGTTTGGAGGCAGCGATACCAGAGCCACC
CGGACGCCGCTGTGCAGAGTCTAGAGATC  
 
 
 
C-terminal PDK1 truncations 
(7) 1485bp 
GGATCCGCCAGGACCACCAGCCAGCTGTATGACGCCGTGCCCATCCAGTCCAGCGTGGTGTTATGTTCCTGCC
CATCCCCATCAATGGTGAGGACCCAGACTGAGTCCAGCACGCCCCCTGGCATTCCTGGTGGCAGCAGGCAGG
GCCCCGCCATGGACGGCACTGCAGCCGAGCCTCGGCCCGGCGCCGGCTCCCTGCAGCATGCCCAGCCTCCGC
CGCAGCCTCGGAAGAAGCGGCCTGAGGACTTCAAGTTTGGGAAAATCCTTGGGGAAGGCTCTTTTTCCACGG
TTGTCCTGGCTCGAGAACTGGCAACCTCCAGAGAATATGCGATTAAAATTCTGGAGAAGCGACATATCATAA
AAGAGAACAAGGTCCCCTATGTAACCAGAGAGCGGGATGTCATGTCGCGCCTGGATCACCCCTTCTTTGTTA
AGCTTTACTTCACATTTCAGGACGACGAGAAGCTGTATTTCGGCCTTAGTTATGCCAAAAATGGAGAACTACT
TAAATATATTCGCAAAATCGGTTCATTCGATGAGACCTGTACCCGATTTTACACGGCTGAGATTGTGTCTGCTT
TAGAGTACTTGCACGGCAAGGGCATCATTCACAGGGACCTTAAACCGGAAAACATTTTGTTAAATGAAGATA
TGCACATCCAGATCACAGATTTTGGAACAGCAAAAGTCTTATCCCCAGAGAGCAAACAAGCCAGGGCCAACT
CATTCGTGGGAACAGCGCAGTACGTTTCTCCAGAGCTGCTCACGGAGAAGTCCGCCTGTAAGAGTTCAGACC
TTTGGGCTCTTGGATGCATAATATACCAGCTTGTGGCAGGACTCCCACCATTCCGAGCTGGAAACGAGTATCT
TATATTTCAGAAGATCATTAAGTTGGAATATGACTTTCCAGAAAAATTCTTCCCTAAGGCAAGAGACCTCGTG
GAGAAACTTTTGGTTTTAGATGCCACAAAGCGGTTAGGCTGTGAGGAAATGGAAGGATACGGACCTCTTAAA
GCACACCCGTTCTTCGAGTCCGTCACGTGGGAGAACCTGCACCAGCAGACGCCTCCGAAGCTCACCGCTTACC
TGCCGGCTATGTCGGAAGACGACGAGGACTGCTATGGCAATTATGACAATCTCCTGAGCCAGTTTGGCTGCAT
GCAGGTGTCTTCGTCCTCCTCCTCACACTCCCTGTCAGCCTCCGACACGGGCCTGCCCCAGAGGTCAGGCAGC
AACATAGAGCAGTACATTCACGATCTGGACTCGAACTCCTTTGAACTGGACTTACAGTTTTCCGAAGATGAGA
AGAGGTTGTTGTTGGAGAAGCAGGCTGGCGGAAACCCTTGGCACCAGTTTGTAGAAAATAATTTAATACTAA
AGATGGGCCCAGTGGATAAGCGGAAGGGTTTATTTGCAAGACGACGACAGCTGTTGCTCACAGAAGGACCA
CATTTATATTATGTGGATCCTGTCAACTAGTCTAGA  
 
(8) 1404bp 
GGATCCGCCAGGACCACCAGCCAGCTGTATGACGCCGTGCCCATCCAGTCCAGCGTGGTGTTATGTTCCTGCC
CATCCCCATCAATGGTGAGGACCCAGACTGAGTCCAGCACGCCCCCTGGCATTCCTGGTGGCAGCAGGCAGG
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GCCCCGCCATGGACGGCACTGCAGCCGAGCCTCGGCCCGGCGCCGGCTCCCTGCAGCATGCCCAGCCTCCGC
CGCAGCCTCGGAAGAAGCGGCCTGAGGACTTCAAGTTTGGGAAAATCCTTGGGGAAGGCTCTTTTTCCACGG
TTGTCCTGGCTCGAGAACTGGCAACCTCCAGAGAATATGCGATTAAAATTCTGGAGAAGCGACATATCATAA
AAGAGAACAAGGTCCCCTATGTAACCAGAGAGCGGGATGTCATGTCGCGCCTGGATCACCCCTTCTTTGTTA
AGCTTTACTTCACATTTCAGGACGACGAGAAGCTGTATTTCGGCCTTAGTTATGCCAAAAATGGAGAACTACT
TAAATATATTCGCAAAATCGGTTCATTCGATGAGACCTGTACCCGATTTTACACGGCTGAGATTGTGTCTGCTT
TAGAGTACTTGCACGGCAAGGGCATCATTCACAGGGACCTTAAACCGGAAAACATTTTGTTAAATGAAGATA
TGCACATCCAGATCACAGATTTTGGAACAGCAAAAGTCTTATCCCCAGAGAGCAAACAAGCCAGGGCCAACT
CATTCGTGGGAACAGCGCAGTACGTTTCTCCAGAGCTGCTCACGGAGAAGTCCGCCTGTAAGAGTTCAGACC
TTTGGGCTCTTGGATGCATAATATACCAGCTTGTGGCAGGACTCCCACCATTCCGAGCTGGAAACGAGTATCT
TATATTTCAGAAGATCATTAAGTTGGAATATGACTTTCCAGAAAAATTCTTCCCTAAGGCAAGAGACCTCGTG
GAGAAACTTTTGGTTTTAGATGCCACAAAGCGGTTAGGCTGTGAGGAAATGGAAGGATACGGACCTCTTAAA
GCACACCCGTTCTTCGAGTCCGTCACGTGGGAGAACCTGCACCAGCAGACGCCTCCGAAGCTCACCGCTTACC
TGCCGGCTATGTCGGAAGACGACGAGGACTGCTATGGCAATTATGACAATCTCCTGAGCCAGTTTGGCTGCAT
GCAGGTGTCTTCGTCCTCCTCCTCACACTCCCTGTCAGCCTCCGACACGGGCCTGCCCCAGAGGTCAGGCAGC
AACATAGAGCAGTACATTCACGATCTGGACTCGAACTCCTTTGAACTGGACTTACAGTTTTCCGAAGATGAGA
AGAGGTTGTTGTTGGAGAAGCAGGCTGGCGGAAACCCTTGGCACCAGTTTGTAGAAAATAATTTAATACTAA
AGATGGGCCCAGTGGATTAGTCTAGA  
5.8 Immunofluorescence 
 
U2OS cells were transfected using SilentFect with wild type PDK1-V5, PDK1-V5-Ub fusion or 
GFP (transfection control) and seeded in chambered slides. Cells were washed with 1x PBS for 5’ and 
fixation was done by incubating with Formaldehyde 4% (MeOH free) for 15min at room 
temperature. The slide was then washed 3x 5’ with PBS at room temperature, incubated 10min at -
20°C covered in 3mm ice-cold MeOH and 5min with PBS at room temperature. Samples were then 
blocked with blocking buffer (as described in the methods) for 60min at room temperature. 
Incubation with primary (anti-V5) antibody (1:200 in Antibody dilution buffer) was done for 3h at 
room temperature. Cells were then washed 3x 5min with PBS and incubated 1h at room 
temperature with secondary fluorophore labelled antibody (Alexa Fluor 488 from invitrogen) at 
1:4000 in antibody dilution buffer (incubation is carried out in the dark). For DAPI staining, the 
secondary antibody is washed away with PBS and DAPI is applied for 3min at room temperature at 
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1:50.000 dilution in antibody dilution buffer. Samples are washed 3x 5min with PBS and the cover is 
mounted with VECTASHIELD mounting medium. Slides can be kept for weeks at 4°C in the dark. 
 
Software. Illustrations were created with Adobe Photoshop CS4. Vector NTI was used for reading 
sequencer output and for plasmid/vector design and drawing.  
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7 Appendix 
7.1 Abbreviations used 
 
HA Haemaglutinin (tag) 
His Histidine (tag) 
AP Affinity purification  
AGC cAMP-dependent, cGMP-dependent, protein kinase C kinase family 
AML Acute myeloid Leukaemia 
DUB Deubiquitinating enzyme 
ESI Electron spray ionisation 
FCS Foetal Calf Serum 
GPCR G-Protein coupled receptor 
IP Immunoprecipitation 
LC Liquid chromatography 
MS Mass spectrometry 
MS/MS Tandem mass spectrometry 
PAGE Polyacrylamide gel electrophoresis 
PI Phosphatidylinositol 
PIP phosphatidylinositol‑phosphate 
PIP2 Phosphatidylinositol-bisphosphate 
PIP3 Phosphatidylinositol-triphosphate 
PM Plasma membrane 
RTK Receptor Tyrosine kinase 
Ub Ubiquitin 
Ubl Ubiquitin-like modifier 
WCL Whole cell lysate 
 
 96 
 
  
 97 
 
7.2 Table of Figures 
 
Figure 1 – Generation of PIP3 by PI3K and dephosphorylation to PIP2 by PTEN .................................... 8 
Figure 2 – The PI3K/AKT Pathway and downstream targets. ................................................................. 9 
Figure 3 – Ubiquitin conjugation steps. ................................................................................................ 19 
Figure 4 – The five DUB Families. ......................................................................................................... 22 
Figure 5 – Target nodes of the PI3K pathway with examples of drugs in use or in clinical 
development. ....................................................................................................................................... 27 
Figure 6 – Small molecule inhibitors of PDK1. Adapted from Garcia-Echeverria et al. 2008 [119] ..... 30 
Figure 7 – PDK1 is mono-ubiquitinated. ............................................................................................... 34 
Figure 8 – Inter species sequence alignment of PDK1. ........................................................................ 35 
Figure 9 – Mapping the mono-ubiquitinated lysine residue. ............................................................... 36 
Figure 10 – Affinity purification (AP) approaches to isolate PDK1-Ubiquitin for MS/MS. ................... 40 
Figure 11 – Affinity purification of ubiquitinated PDK1 and silver staining. ........................................ 41 
Figure 12 – MASCOT readout from MS/MS analysis of A05 and A06 trypsin digested bands. ............ 45 
Figure 13 – Loss of function screen for a DUB acting on PDK1. ........................................................... 47 
Figure 14 – Functional characterization of PDK1 mono-ubiquitination. .............................................. 50 
  
 98 
 
7.3 Zusammenfassung 
 
 Durch die Aktivität der zentralen Effektorkinase AKT (PKB) spielt der PI3K/AKT Singalweg 
eine wichtige Rolle bei der Transduktion von anti-apoptotischen Signalen in Zellteilung und 
Zellproliferation. Weiters besteht ein Zusammenhang zwischen der Deregulation des PI3K/AKT 
Signalwegs und dem Auftreten zahlreicher maligner Erkrankungen wie Brust- und Prostatakrebs und 
der Entstehung von Glioblastomen. Dies macht die Komponenten dieses Signaltransduktionsweges 
zu wichtigen therapeutischen Zielen. Die Aktivierung von AKT ist abhängig von der Kinase 
phosphoinositide-dependent kinase 1 (PDK1), welche AKT unter Mitwirkung von PIP3 aktiviert, und 
so als essentieller Hauptaktivator für AKT fungiert. PDK1 aktiviert auch weitere downstream 
Proteine der AGC Familie, welche eine wichtige Rolle für Metabolismus und Translation spielen. Es 
ist etabliert, dass PDK1 konstitutiv aktiv ist und Wachstumsfaktor- und Insulinsignaltransduktion 
indirekt die Fähigkeit von PDK1 beinflussen Substrate zu binden. Die Regulation von PDK1 ist jedoch 
nicht zur Gänze aufgeklärt. Weiters hat PDK1 im Laufe der letzten Jahre als therapeutisches 
Zielprotein an Popularität gewonnen und mehrere Inhibitoren befinden sich in klinischer Testphase. 
Erstmals wird mit der vorliegenden Arbeit gezeigt, dass PDK1 monoubiquitiniert ist. Zudem sollen 
die Position, die Rolle und die molekularen Antagonisten dieser posttranslationalen Modifikation 
charakterisiert werden. Ubiquitin ist bekannt für seine Rolle in proteosomaler Degradation, jedoch 
können verschiedene Typen von konjugierten Ubiquitinepitopen auch Lokalisation, Aktivität und 
Konformation von ubiqutinierten Proteinen beeinflussen. Die Chrakaterisierung der PDK1 
Monoubiquitinierung verspricht neue Einsicht in die Regulationsmechanismen von PDK1 in 
normalen und transformierten Zellen zu gewinnen. Weiters wird das Ubiquitinsystem zunehmend 
als therapeutisches Ziel betrachtet, da es auf enzymatischen Reaktionen basiert, die potentiell durch 
niedermolekulare Substanzen inhibiert werden können. Dies eröffnet die Möglichkeit 
Monoubiquitinierung als alternativen Winkel auszunutzen um den PI3K/AKT Signalweg über PDK1 zu 
inhibieren. Dieses Projekt versucht die Position der ubiqutinierten Aminosäure in PDK1 durch 
Mutagenese, Truncations, und Massenspektrometrie zu identifizieren. Obzwar die genaue Position 
des ubiquitinierten Aminosäurerests nicht definiert werden konnte, konnte die 
Monoubiquitinierungsstelle der Kinasendomäne zugeordnet werden. Zudem wurde versucht durch 
Experimente zu intrazellulärer Lokalisation, katalytischer Aktivität und PIP3 Bindung, die Funktion 
der Monoubiquitinierung zu ergründen. Den hier beschriebenen Resultaten zufolge ist 
auszuschließen, dass PDK1 Monoubiquitinierung PIP3 Bindung beeinflusst und dass diese keine 
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Vorraussetzung für die Monoubiquitinierung von PDK1 ist. Die Position von PDK1 und seine 
Fähigkeit AKT zu phosphorylieren waren auch nicht von Monoubiquitinierung abhängig. Letztlich 
haben wir einen „Loss of function“ RNA-Interferenzscreen durchgeführt um eine PDK1 spezifische 
Deubiquitinase (DUB) zu identifizieren. Es wurde allerdings keine DUB gefunden. Obwohl die 
Charakterisierung der Monoubiquitinierung weitere Arbeit verlangen wird, haben wir die erste post-
translationale Modifikation von PDK1 durch Ubiquitin beschrieben. 
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7.4 Abstract 
 
The PI3K/AKT signaling pathway mediates anti-apoptotic signals and drives cell growth and 
proliferation via the activity of its central effector kinase AKT (PKB). Deregulation of the PI3K/AKT 
pathway has been linked to a large number of human malignancies such as glioblastoma, breast and 
prostate cancer, which makes its components interesting targets for therapy. Activation of AKT 
depends on the action of phosphoinositide-dependent kinase 1 (PDK1), which phosphorylates and 
activates AKT in a PIP3 dependent manner, and thus acts as an essential master activator of the 
pathway. PDK1 also activates other downstream targets of the AGC kinase family that drive 
metabolism and translation. It is established that PDK1 is constitutively active and that insulin and 
growth factor signaling indirectly affect PDK1's ability to bind its substrates, yet its regulation is 
incompletely understood. Furthermore PDK1 has gained popularity as a therapeutic target over the 
last years, and several inhibitors have been identified which are currently being tested in clinical 
trials. Here we show for the first time that PDK1 is mono-ubiquitinated and have attempted to 
elucidate the site, role and molecular antagonists of this post translational modification. 
Ubiquitination is known for its role in proteasomal degradation, but depending on the type of 
conjugated ubiquitin epitope, can also influence localization, activity and conformation of the 
ubiquitinated protein. Identifying the role of PDK1 mono-ubiquitination may give novel mechanistic 
insight into PDK1 regulation in normal and transformed cells. Additionally, the ubiquitin system is 
increasingly considered as a therapeutic target because it involves enzymatic reactions which can 
potentially be inhibited with low molecular compounds. This raises the possibility that mono-
ubiquitination may be exploited as an alternative angle to target the PI3K/AKT pathway via PDK1 in 
cancer. In this project we have attempted to map the ubiquitinated lysine residue by mutagenesis, 
truncation experiments and mass spectrometry. We were able to map the ubiquitination site to the 
kinase domain, but finding the specific ubiquitinated residue will require further efforts. We have 
also attempted to identify the function of this post-translational modification by investigating 
localization, catalytic activity and PIP3 binding. We were able to exclude that PDK1 mono-
ubiquitination affects PIP3 binding and that it is dependent on it. Our data also suggests that 
localization and PDK1’s ability to phosphorylate AKT are not affected by mono-ubiquitin. Finally an 
RNAi loss of function screen was performed to identify a de-ubiquitinase (DUB), but no DUB was 
found. Although our efforts to characterize PDK1 mono-ubiquitination will require further work, we 
have described the first post-translational modification of PDK1 by ubiquitin. 
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